epirubicin has been researched along with Lymph Node Metastasis in 231 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (0.87) | 18.7374 |
| 1990's | 51 (22.08) | 18.2507 |
| 2000's | 96 (41.56) | 29.6817 |
| 2010's | 78 (33.77) | 24.3611 |
| 2020's | 4 (1.73) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, Y; Kang, Y; Li, Q; Luo, Y; Ma, F; Wang, J; Wang, X; Xu, B; Yuan, P; Yue, J; Zhang, P | 1 |
| Bins, AD; de Vries, EGE; Gietema, JA; Hooning, MJ; Jacobse, JN; Jager, A; Konings, IR; Kroep, JR; Linn, SC; Schaapveld, M; Schröder, CP; Seynaeve, CM; Smit, WM; Sonke, GS; Steenbruggen, TG; Steggink, LC; Tjan-Heijnen, VCG; van der Hoeven, JJM; van der Wall, E; van Leeuwen, FE; van Tinteren, H | 1 |
| Fan, Z; He, Y; Li, J; Li, Y; Ouyang, T; Wang, L; Wang, T; Xie, Y | 1 |
| Chen, C; Jia, Y; Ke, XK; Peng, J; Pu, H; Zhou, Q | 1 |
| Chen, CS; Cheng, CL; Chiu, KY; Ho, HC; Hung, SC; Li, JR; Ou, YC; Wang, SS; Yang, CK | 1 |
| Funakoshi, T; Hirai, I | 1 |
| Bae, SY; Kim, I; Kim, SW; Lee, JE; Lee, SK; Nam, SJ; Paik, HJ; Park, S; Ryu, JM; Yu, J | 1 |
| Fitzgerald, RC; Griffiths, E; Lloyd, MA; Mercer, S; Noble, F; O'Donovan, M; O'Neill, JR; Parsons, SL; Turkington, R; Underwood, TJ | 1 |
| Chen, S; Gui, A; Li, Z; Ling, F; Ma, S; Sun, Y | 1 |
| du Bois, A; Harbeck, N; Hinke, A; Huober, J; Jackisch, C; Konecny, GE; Kuhn, W; Kurbacher, C; Lück, HJ; Möbus, V; Nitz, U; Runnebaum, IB; Schneeweiss, A; Thomssen, C; Untch, M; von Minckwitz, G | 1 |
| Cao, M; Deng, H; Liu, J; Rao, N; Wu, W; Yang, Y; You, N | 1 |
| Aparicio, T; Azzedine, A; Barbier, E; Bouche, O; Chapelle, N; Cohen, R; Dahan, L; Etienne, PL; Gornet, JM; Guimbaud, R; Hammel, P; Le Malicot, K; Lepage, C; Louvet, C; Mineur, L; Nguyen, S; Phelip, JM; Samalin, E; Sefrioui, D; Touchefeu, Y | 1 |
| Cabral, H; Chida, T; Kataoka, K; Miura, Y; Nishiyama, N; Nomoto, T | 1 |
| He, XM; Xiang, H; Yang, HJ; Yu, Y; Zong, XY | 1 |
| Bono, P; Claes, B; Fumagalli, D; Joensuu, H; Kataja, V; Kellokumpu-Lehtinen, PL; Lambrechts, D; Loi, S; Michiels, S; Piccart, MJ; Sotiriou, C | 1 |
| Audhuy, B; Berdah, JF; Buyse, M; Delbaldo, C; Greget, S; Laplaige, P; Mousseau, M; Piedbois, P; Priou, F; Quinaux, E; Serin, D; Teissier, E; Zelek, L | 1 |
| Boughey, JC; Buzdar, AU; Ellis, MJ; Ewer, MS; Hunt, KK; Leitch, AM; McCall, LM; Meric-Bernstam, F; Royce, M; Suman, VJ; Unzeitig, G | 1 |
| Bailey, IS; Byrne, JP; Curtis, NJ; Kelly, JJ; Noble, F; Underwood, TJ | 1 |
| Namikawa, K; Oashi, K; Omata, W; Tanaka, R; Tsutsumida, A; Yamamoto, Y; Yamazaki, N | 1 |
| Abraham, J; Caldas, C; Chan, S; Dean, S; Dunn, J; Earl, HM; Fenwick, N; Gallagher, C; Gounaris, I; Harries, M; Hickish, T; Hiller, L; Houston, S; Hughes-Davies, L; Iddawela, M; Laing, R; McAdam, K; Provenzano, E; Ritchie, D; Skene, A; Vallier, AL; Wishart, G; Young, J | 1 |
| Aieta, M; Ballestrero, A; Bengala, C; Bregni, M; Bruno, B; Castagna, L; Cinieri, S; Da Prada, GA; De Giorgi, U; Fedele, R; Frassineti, GL; Gianni, AM; Grasso, D; Lanza, F; Martinelli, G; Martino, M; Pedrazzoli, P; Rosti, G; Secondino, S | 1 |
| Bailey, IS; Bateman, AC; Bateman, AR; Byrne, JP; Iveson, TJ; Kelly, JJ; Noble, F; Nolan, L; Rees, CN; Sharland, DM; Underwood, TJ | 1 |
| Cao, J; Huang, XE; Liu, J; Lu, YY; Wu, XY | 1 |
| Blaskowsky, LS; Enzinger, PZ; Hong, TS; Kwak, EL; Mamon, HJ; Mullen, JT; Ryan, DP; Schoenfeld, JD; Wo, JY | 1 |
| Hayashi, N; Kajiura, Y; Matsuda, N; Nakamura, S; Ohde, S; Suzuki, K; Tsunoda, H; Yagata, H; Yamauchi, H; Yoshida, A | 1 |
| Alba, E; Brase, JC; Caballero, R; Calvo, L; Carrasco, E; Casas, M; Crespo, C; Fisch, K; Krappmann, K; Kronenwett, R; Martin, M; Munarriz, B; Petry, C; Rodriguez, CA; Rodriguez-Lescure, A; Ruiz, A; Ruiz-Borrego, M; Weber, KE | 1 |
| Chi, Y; Song, Y; Wang, J; Yang, L; Zhou, A | 1 |
| Andergassen, U; Beckmann, MW; Fasching, PA; Fehm, T; Friedl, TW; Friese, K; Hepp, P; Janni, W; Jückstock, J; Lichtenegger, W; Lorenz, R; Pantel, K; Rack, B; Schindlbeck, C; Schneeweiss, A; Tesch, H; Zwingers, T | 1 |
| Babu, S; Das, U; Govind Babu, K; Jacob, L; Lakshmaiah, KC; Lokanatha, D; Suresh, TM | 1 |
| Cihan, YB | 1 |
| Cao, J; Guo, W; Huang, M; Ji, D; Li, J; Liu, X; Peng, W; Sun, S; Wang, C; Yin, J; Yu, H; Zhao, X; Zhu, X | 1 |
| Akahane, K; Fujii, M; Kawada, K; Murata, T; Oda, K; Ohama, T; Yatabe, Y | 1 |
| Abrial, C; Bensussan, A; Curé, H; de Boissieu, P; Garbar, C; Kwiatkowski, F; Mombelli, S; Wang-Lopez, Q | 1 |
| Ardizzoni, A; Barni, S; Bighin, C; Bisagni, G; Boni, C; Bruzzi, P; Cavazzini, G; Cognetti, F; Colantuoni, G; De Laurentiis, M; De Placido, S; Del Mastro, L; Durando, A; Forestieri, V; Gamucci, T; Garrone, O; Giuliano, M; Gravina, A; Montemurro, F; Nisticò, C; Papaldo, P; Puglisi, F; Turletti, A; Valle, E | 1 |
| de Jongh, FE; Drooger, JC; Jager, A; Leunis, C; van Pelt-Sprangers, JM | 1 |
| Baretton, GB; Froehner, M; Hakenberg, OW; Heberling, U; Hübler, M; Koch, R; Novotny, V; Oehlschlaeger, S; Wirth, MP | 1 |
| Adrover, E; Andrés, R; Baena-Cañada, JM; Ballesteros, AI; Barnadas, A; Calvo, L; Carrasco, EM; Casas, M; de la Haba-Rodríguez, J; Del Barco Berron, S; del Carmen Cámara, M; González, S; Jara, C; Lluch, A; López-Vega, JM; Margelí Vila, M; Martín, M; Martínez de Dueñas, E; Martínez-Jáñez, N; Mendiola Fernández, C; Muñoz-Mateu, M; Plazaola, A; Ramos, M; Ribelles, N; Rodríguez, CA; Rodríguez-Lescure, Á; Ruiz Borrego, M; Ruiz Simón, A; Sánchez-Rovira, P; Santaballa, A | 1 |
| Fox, MJ; Gibbs, P; Pickles, MD | 1 |
| Augustin, D; Erber, R; Gluz, O; Harbeck, N; Hartmann, A; Hoffmann, G; Huober, J; Jänicke, F; Kates, RE; Kiechle, M; Kreipe, HH; Kuhn, W; Liedtke, C; Möbus, V; Mohrmann, S; Nitz, U; Pelz, E; Peyro-Saint-Paul, H; Thomssen, C; Wallwiener, D | 1 |
| Annecke, K; Augustin, D; Friedl, TW; Harbeck, N; Huober, J; Janni, W; Jueckstock, J; Kiechle, M; Rack, B; Scholz, C; Wischnik, A; Zwingers, T | 1 |
| Allum, WH; Braconi, C; Cunningham, D; Fassan, M; Ghidini, M; Grabsch, HI; Hahne, JC; Lampis, A; Langley, R; Nankivell, M; Okines, AF; Peckitt, C; Rugge, M; Smyth, EC; Valeri, N; Wotherspoon, A | 1 |
| Du, J; Fan, L; Jiang, J; Liang, Q; Liu, J; Ming, J; Zhang, Y; Zhong, L | 1 |
| Denkert, C; Eiermann, W; Furlanetto, J; Lederer, B; Loibl, S; Marmé, F; Möbus, V; Nekljudova, V; Reimer, T; Reinisch, M; Schmatloch, S; Stickeler, E; Thomssen, C; Untch, M; von Minckwitz, G; Weber, K | 1 |
| Athanasiadis, A; Boukovinas, I; Georgoulias, V; Kakolyris, S; Katsaounis, P; Kentepozidis, N; Malamos, N; Matikas, A; Mavroudis, D; Papakotoulas, P; Saloustros, E; Ziras, N | 1 |
| Chen, S; Di, GH; Jiang, YZ; Jin, X; Shao, ZM | 1 |
| Collignon, J; Delvenne, P; Donneau, AF; Feyereisen, E; Foidart, P; Gofflot, S; Jerusalem, G; Lienard, M; Noël, A; Schroeder, H; Somja, J; Sounni, NE; Truong, A; Yip, C | 1 |
| Anan, K; Hirose, N; Mitsuyama, S; Ogawa, S; Saimura, M; Shimada, K; Tamaki, N; Tamura, K; Tanaka, M; Tomisaki, S | 1 |
| Bae, SH; Choi, IB; Choi, JY; Han, CW; Jang, JW; Jung, HS; Kay, CS; Kim, CW; Yoon, SK; You, CR | 1 |
| Bataille, R; Campion, L; Campone, M; Charbonnel, C; Genève, J; Gouraud, W; Jézéquel, P; Magrangeas, F; Martin, AL; Minvielle, S; Ricolleau, G; Roché, H | 1 |
| Cai, RG; Li, Q; Wang, JY; Wu, WH; Xu, BH; Yuan, P; Zhang, P; Zhao, LM; Zhou, AP | 1 |
| Bae, JS; Chae, BJ; Jung, SS; Kim, JS; Lee, A; Park, WC; Seo, YJ; Song, BJ | 1 |
| André, F; Antoine, M; Asselain, B; Baranzelli, MC; Bibeau, F; Denoux, Y; Jacquemier, J; Lacroix-Triki, M; Lagarde, N; Martin, AL; Penault-Llorca, F; Roché, H; Sagan, C; Verriele, V | 1 |
| Bearz, A; Berretta, M; Canzonieri, V; Ciancia, EM; Gobitti, C; Martellotta, F; Pavone, P; Taibi, R; Tirelli, U; Zanet, E | 1 |
| Asaga, T; Chishima, T; Doi, T; Hamaguchi, Y; Ichikawa, Y; Inaba, M; Ishikawa, T; Kasahara, A; Katayama, K; Kito, A; Matsumoto, C; Momiyama, N; Morita, S; Narui, K; Ohta, I; Shimada, H; Shimizu, D; Shimizu, S; Suda, T; Tanabe, M; Yamaguchi, N; Yoshimoto, M | 1 |
| Abe, R; Kimijima, I; Kimura, M; Koyama, H; Miura, S; Nomura, Y; Ohashi, Y; Takashima, S; Takatsuka, Y; Tashiro, H; Toi, M; Tominaga, T | 1 |
| Chen, CM; Di, GH; Hou, YF; Hu, Z; Huang, O; Liu, GY; Lu, JS; Shao, ZM; Shen, KW; Shen, ZZ; Wu, J; Wu, JY; Zhang, JX | 1 |
| Fu, JF; Hong, ZW; Wang, B | 1 |
| Adamou, A; Athanasiadis, A; Boukovinas, I; Christophyllakis, C; Georgoulias, V; Kakolyris, S; Kalbakis, K; Karvounis, N; Kouroussis, C; Malamos, N; Mavroudis, D; Papakotoulas, P; Polyzos, A; Syrigos, K; Vamvakas, L; Varthalitis, I; Ziras, N | 1 |
| Ataseven, B; Conrad, B; Eiermann, W; Graf, E; Hilfrich, J; Kaufmann, M; Loibl, S; Massinger-Biebl, H; Schumacher, M; Vescia, S; von Minckwitz, G | 1 |
| Alanko, T; Asola, R; Auvinen, P; Bono, P; Helle, L; Huusko, M; Ingalsuo, S; Isola, J; Joensuu, H; Jyrkkiö, S; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Leinonen, H; Leinonen, M; Möykkynen, K; Pajunen, M; Salminen, T; Turpeenniemi-Hujanen, T; Utriainen, T | 1 |
| Albain, KS; Bramwell, V; Burnell, M; Chalchal, H; Chapman, JA; Gelmon, K; Levine, MN; O'Brien, P; Perez, EA; Pritchard, K; Rugo, H; Shepherd, LE; Vandenberg, T; Walley, B | 1 |
| Bourgeois, H; Campone, M; Canon, JL; Coudert, B; Delozier, T; Extra, JM; Hardy-Bessard, AC; Kerbrat, P; Kramar, A; Lortholary, A; Machiels, JP; Maerevoet, M; Martin, AL; Orfeuvre, H; Penault-Llorca, F; Piot, G; Roché, H; Romieu, G; Serin, D; Spielmann, M | 1 |
| Bao, Y; Fan, CG; Jiang, J; Li, GL; Li, JS; Li, N | 1 |
| Ben Salah, H; Boudawara, T; Daoud, J; Frikha, M; Gargouri, R; Ghorbel, A; Ghorbel, L; Karray, H; Khabir, A; Toumi, N | 1 |
| du Bois, A; Harbeck, N; Hinke, A; Huober, J; Jackisch, C; Konecny, GE; Kreienberg, R; Kuhn, W; Kurbacher, C; Lueck, HJ; Moebus, V; Nitz, U; Runnebaum, IB; Schneeweiss, A; Thomssen, C; Untch, M; von Minckwitz, G | 1 |
| Ebert, M; Grenacher, L; Lordick, F; Moehler, M; Röcken, C; Schumacher, G | 1 |
| Amadori, D; Amaducci, L; Baldini, E; Biglia, N; Boccardo, F; Bonginelli, P; Brandi, M; De Lena, M; Faedi, M; Gianni, L; Maltoni, R; Paradiso, A; Ponzone, R; Rocca, A; Scarpi, E; Schittulli, F; Serra, P; Silvestrini, R; Tienghi, A; Valerio, MR | 1 |
| Candeloro, G; Desideri, G; Necozione, S; Piazze, J; Rea, S; Recchia, CO; Recchia, F | 1 |
| Cegovnik, U; Kern, I; Korošec, P; Košnik, M; Rijavec, M; Silar, M; Triller, N | 1 |
| Baak, JP; Gilje, B; Janssen, EA; Nordgård, O; Smaaland, R; Søiland, H; Tjensvoll, K | 1 |
| Augustin, D; Hanf, V; Harbeck, N; Jaenicke, F; Kantelhardt, EJ; Martin, PM; Meisner, C; Paepke, D; Schmidt, M; Schmitt, M; Sweep, F; Thomssen, C; Vetter, M; Veyret, C; von Minckwitz, G | 1 |
| Blijham, GH; Erdkamp, FL; Knibbeler-van Rossum, CT; Lalisang, RI; Loosveld, OJ; Nortier, JW; Rodenburg, CJ; Schouten, HC; Slee, PH; Smals, AE; Tjan-Heijnen, VC; van Bochove, A; Voest, EE; Wals, J; Wils, JA | 1 |
| Andrieu, JM; Bats, AS; Eme, D; Hofmann, H; Huchon, C; Le Frere-Belda, MA; Lecuru, F; Levy, E; Medioni, J; Oudard, S | 1 |
| Baba, Y; Kim, SJ; Kishi, K; Nakayama, T; Naoi, Y; Noguchi, S; Shimazu, K; Shimomura, A; Tamaki, Y; Yasojima, H | 1 |
| Bliss, JM; Coleman, RE; Coombes, RC; Cooper, D; den Boer, MO; Erdkamp, F; Espie, M; Hupperets, P; Kilburn, LS; Marty, M; Reise, JA; Thomas, MW; Tres, A; Tubiana-Mathieu, N; Wals, J; Wardley, A; Wilkinson, K | 1 |
| Lolkema, MP; van der Horst, S; van der Sluis, PC; van Hillegersberg, R; Verhage, RJ | 1 |
| Ashley, S; Chau, I; Cunningham, D; Gujral, DM; Hawkins, MA; Leonulli, BG; Tait, D | 1 |
| Chen, SF; Gong, C; Luo, M; Su, FX; Yao, HR; Zeng, YJ | 1 |
| Brandi, M; Colucci, G; Di Benedetto, A; Di Lauro, L; Filippelli, G; Foggi, P; Gebbia, N; Giannarelli, D; Giotta, F; Lopez, M; Massidda, B; Mottolese, M; Schittulli, F; Vici, P | 1 |
| Farkas, R; Horváth, OP; Kálmán, E; Kovács, G; Kövér, E; Pavlovics, G; Szalai, G; Tizedes, G; Zapf, I | 1 |
| Kasumi, F; Kosaka, T; Saito, M; Shimizu, H; Taira, F | 1 |
| Chen, CM; Chen, S; Shao, ZM; Yang, WT; Yu, KD | 1 |
| Ahlgren, J; Asola, R; Auvinen, P; Bono, P; Helle, L; Huovinen, R; Joensuu, H; Jukkola-Vuorinen, A; Kataja, V; Kellokumpu-Lehtinen, PL; Kokko, R; Leinonen, M; Lindman, H; Nilsson, G; Nyandoto, P; Paija, O; Pajunen, M; Poikonen, P; Tanner, M; Villman, K | 1 |
| Bafaloukos, D; Batistatou, A; Bobos, M; Briasoulis, E; Christodoulou, C; Dafni, U; Dimopoulos, MA; Eleftheraki, AG; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Kosmidis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Samantas, E; Stathopoulos, GP; Timotheadou, E | 1 |
| Bassi, N; D'Amico, FE; Dei Tos, AP; Massani, M; Romeo, S; Ruffolo, C | 1 |
| Kang, WM; Ma, ZQ; Wang, J; Yu, JC | 1 |
| Fu, J; Leng, H; Liang, L; Liu, YL; Xing, W; Zhang, HW | 1 |
| Abe, H; Cho, H; Kawai, Y; Kubota, Y; Kurumi, Y; Mori, T; Tani, T; Umeda, T | 1 |
| Bouchardy, C; Dehler, S; Ess, S; Frick, H; Joerger, M; Konzelmann, I; Savidan, A; Thürlimann, B | 1 |
| Nakamura, K; Okuyama, R; Saida, T; Uhara, H | 1 |
| Asselain, B; Audhuy, B; Beauduin, M; Campone, M; Canon, JL; Coudert, B; Eymard, JC; Jerusalem, G; Lévy, C; Machiels, JP; Martin, AL; Orfeuvre, H; Pénault-Llorca, F; Petit, T; Piot, G; Roché, H; Romieu, G; Serin, D; Spielmann, M; Veyret, C | 1 |
| Akiyama, F; Aogi, K; Ikeda, T; Kashiwaba, M; Kuroi, K; Kurosumi, M; Masuda, N; Miyakoda, K; Nakamura, S; Nishimura, R; Ohno, S; Rai, Y; Saeki, T; Sato, N | 1 |
| Abotouk, N; Halim, A | 1 |
| Chen, J; Chen, YJ; Li, HJ; Lv, Q; Tian, CX; Wang, XD; Yang, Q | 1 |
| Anter, AH; Hamed, RH; Sakr, H; Yossef, T | 1 |
| Bella, M; Bisagni, G; Boni, C; Bruzzi, P; Camisa, R; Ceci, G; Cocconi, G; Di Blasio, B; Leonardi, F; Rondini, E; Savoldi, L | 1 |
| Brundage, M; Chin, JL; Lukka, H; Markman, BR; Segal, R; Winquist, E | 1 |
| Brémond, A; Clavère, P; Datchary, J; Facchini, T; Fargeot, P; Fumoleau, P; Goudier, MJ; Jacquin, JP; Kerbrat, P; Luporsi, E; Mihura, J; Monnier, A; Namer, M; Pourny, C; Ramos, R; Romestaing, P; Schraub, S; Seffert, P; Serin, D; Sztermer, JF | 1 |
| Dörken, B; Krenn, V; Kretzschmar, A; Reichardt, P; Thuss-Patience, PC | 1 |
| Etrych, T; Jelínková, M; Kovár, M; Kubácková, K; Mrkvan, T; Plocová, D; Pokorná, J; Ríhová, B; Rozprimová, L; Sírová, M; Strohalm, J; Ulbrich, K | 1 |
| Amat, S; Bouchet Mishellany, F; Cayre, A; Chollet, P; De Latour, M; Feillel, V; Ferrière, JP; Le Bouedec, G; Penault-Llorca, F | 1 |
| Amdur, RJ; Hinerman, RW; Mendenhall, WM; Monroe, AT; Morris, CG | 1 |
| Iwahashi, M; Nakamori, M; Nakamura, M; Yamaue, H | 1 |
| Damon, L; Demirer, T; Derigs, G; Ferrante, P; Kröger, N; Rosti, G; Wandt, H; Zander, AR | 1 |
| Breitbach, P; Eggemann, H; Elling, D; Kohls, A; Krocker, J; Kümmel, S; Morack, G; Schlosser, H | 1 |
| Bruzzi, P; Conte, P; Donati, S; Gennari, A; Guarneri, V; Landucci, E; Orlandini, C; Ricci, S; Rondini, M; Salvadori, B | 1 |
| Aebersold, DM; Altermatt, HJ; Berclaz, G; Djonov, V; Greiner, RH; Gruber, G; Hlushchuk, R | 1 |
| Nishiura, K; Obata, H; Okugawa, T; Tabata, T; Tanaka, K; Toyoda, N; Yanoh, K | 1 |
| Barats, JC; Bonneterre, J; Chapelle-Marcillac, I; Clavère, P; Datchary, J; Fargeot, P; Fumoleau, P; Goudier, MJ; Kerbrat, P; Monnier, A; Montcuquet, P; Roché, H; Van Praagh, I; Veyret, C | 1 |
| Okazaki, Y; Yamada, T; Yuyama, Y | 1 |
| Ardizzoia, A; Barni, S; Biasioli, R; Freddi, E; Frontini, L; Grassi, MM; Lucani, L; Mandalà, M; Nosenzo, MA; Piazza, E; Pravettoni, A; Recalcati, A; Rezzani, C; Sala, R; Trabucchi, E; Villa, S; Visini, M | 1 |
| Barats, JC; Bonneterre, J; Campone, M; Chapelle-Marcillac, I; Fargeot, P; Goudier, MJ; Guastalla, JP; Lortholary, A; Monnier, A; Namer, M; Roché, H; Schraub, S; Van Praagh, I | 1 |
| Cui, HJ; Li, Y; Tan, HY; Wu, XQ | 1 |
| Byun, JH; Choi, MG; Chung, IS; Hong, YS; Kang, JH; Kim, KW; Lee, KS; Lee, MA; Moon, DH; Park, SY; Shim, BY; Woo, IS | 1 |
| Bonneterre, JM | 1 |
| Radice, D; Redaelli, A | 1 |
| Barone, C; D'Ugo, D; La Torre, G; Persiani, R; Picciocchi, A; Pozzo, C; Rausei, S; Ricci, R; Sermoneta, D | 1 |
| Abali, H; Altundag, K; Atahan, IL; Baltali, E; Engin, H; Erman, M; Guler, N; Karaoglu, A; Onat, D; Ozisik, Y; Sayek, I; Tekuzman, G | 1 |
| Andersen, PK; Dombernowsky, P; Nielsen, D; Osterlind, K; Ryberg, M; Skovsgaard, T | 1 |
| Alliot, C | 1 |
| Avril, N; Bader, M; Dose Schwarz, J; Hemminger, G; Jänicke, F; Jenicke, L | 1 |
| Aoki, T; Arima, M; Hakamada, Y; Kaise, H; Kubouchi, T; Kusama, M; Ota, D; Tokita, H; Tsuchida, A | 1 |
| Pan, CE; Wu, WJ; Zeng, J | 2 |
| Bighin, C; Cappuzzo, F; Del Mastro, L; Durando, A; Lambiase, A; Monfardini, S; Nicoletto, O; Olmeo, N; Puglisi, F; Venturini, M | 1 |
| Kim, SJ; Miyoshi, Y; Noguchi, S; Taguchi, T; Tamaki, Y; Tanji, Y | 1 |
| Franzaring, L; Lehmann, J; Stöckle, M; Thüroff, J; Wellek, S | 1 |
| Chen, L; Jiang, WZ; Lu, YF; Pan, CE; Wu, WJ; Zeng, J | 1 |
| Blohmer, JU; Breitbach, GP; Budner, M; Elling, D; Kohls, A; Krocker, J; Kümmel, S; Lichtenegger, W; Morack, G | 1 |
| Baltas, D; Filipowicz, I; Hoffmann, G; Kolotas, C; Kontova, M; Kuner, RP; Kurek, R; Martin, T; Pollow, B; Roddiger, SJ; Rogge, B; Zamboglou, N | 1 |
| Hamada, K; Kubota, K; Mori, S; Nakagawa, A; Suzuki, N; Tagaya, N | 1 |
| Aebi, S; Basser, RL; Castiglione-Gertsch, M; Cinieri, S; Coates, AS; Gelber, RD; Goldhirsch, A; Green, MD; Martinelli, G; O'Neill, A; Peccatori, F; Price, KN; Viale, G | 1 |
| Chen, CM; Cheng, SH; Clarke, JL; Horng, CF; Huang, AT; Jian, JJ; Liu, MC; Prosnitz, LR; Tsai, SY; Tsou, MH; West, M | 1 |
| Dohden, K; Hattori, M; Hayashi, H; Hosokawa, O; Kaizaki, Y; Kiya, T; Morishita, M; Morita, M; Ohta, K | 1 |
| Ito, Y; Tokudome, N | 1 |
| Blohmer, JU; Breitbach, GP; Budner, M; Elling, D; Kohls, A; Krocker, J; Kümmel, S; Morack, G | 1 |
| Ben Yosef, R; Sarid, D; Shalmon, A; Sperber, F; Weinstein, Y; Yaal-Hahoshen, N | 1 |
| Battelli, N; Braconi, C; Cascinu, S; Cobelli, S; Dinota, A; Giacomini, G; Giorgi, F; Manzione, L; Massacesi, C; Morale, D; Pilone, A; Scanni, A; Sturba, F; Tummarello, D | 1 |
| Biesma, B; Bolhuis, RJ; Paul, MA; Phernambucq, EC; Postmus, PE; Schramel, FM; Smit, EF; vd Tol, A | 1 |
| Ito, Y; Tomono, H; Watanabe, T | 1 |
| Angellier, E; Berdah, JF; Buyse, M; Fabbro, M; Greget, S; Herait, P; Jehl, V; Laplaige, P; Piedbois, P; Priou, F; Serin, D; Teissier, E; Valenza, B | 1 |
| Karakuzu, A; Koc, M; Ozdemir, S | 1 |
| Asselain, B; Bonneterre, J; Campone, M; Canon, JL; Delozier, T; Eichler, F; Ferrero, JM; Fumoleau, P; Genève, J; Goudier, MJ; Kerbrat, P; Martin, AL; Monnier, A; Roché, H; Serin, D; Soulié, P; Spielmann, M; Symann, M; Viens, P; Vindevoghel, A | 1 |
| Calpena, R; Cansado Martínez, P; Lacueva Gómez, FJ; Martínez Banaclocha, N; Merck, B; Pérez Ramos, M | 1 |
| Boudawara, T; Daoud, J; Frikha, M; Kallel, F; Khanfir, A; Meziou, M; Mnif, J; Trabelsi, K | 1 |
| Ames, FC; Babiera, GV; Feig, BW; Francis, A; Gilcrease, MZ; Hunt, KK; Kuerer, HM; Meric-Bernstam, F; Ross, MI; Shen, J | 1 |
| Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Gelber, RD; Gelber, S; Goldhirsch, A; Pagani, O; Price, KN; Simoncini, E | 1 |
| Aitini, E; Ardizzoia, A; Arnoldi, E; Barni, S; Barone, C; Beretta, GD; Bertetto, O; Carnaghi, C; Cascinu, S; Cassano, A; Catalano, V; Chiara, S; Cortesi, E; Floriani, I; Foa, P; Frontini, L; Gasparini, G; Giordani, P; Labianca, R; Mansutti, M; Mosconi, S; Nardi, M; Piazza, E; Pozzo, C; Pucci, F; Rabbi, C; Ravaioli, A; Rimassa, L; Rota, S; Santoro, A; Silva, RR; Sobrero, A; Torri, V | 1 |
| Baruch, NB; Biran, H; Dinerman, M; Idelevich, E; Karminsky, N; Katsenelson, RL; Man, S; Shani, A; Zvi, NB | 1 |
| Audhuy, B; Bonneterre, J; Chollet, P; Clavère, P; Eymard, JC; Fargeot, P; Fumoleau, P; Goudier, MJ; Guastalla, JP; Kerbrat, P; Lortholary, A; Monnier, A; Montcuquet, P; Namer, M; Roché, H; Simon, H; Veyret, C; Walter, S | 1 |
| Galid, A; Gnant, M; Greil, R; Haid, A; Jakesz, R; Klug, E; Kubista, E; Kwasny, W; Lang, A; Luschin-Ebengreuth, G; Menzel, C; Mlineritsch, B; Pöstlberger, S; Rudas, M; Samonigg, H; Singer, CF; Steger, GG; Tausch, C; Wenzel, C | 1 |
| Bataille, R; Campion, L; Campone, M; Charbonnel, C; Genève, J; Gouraud, W; Jézéquel, P; Magrangeas, F; Martin, AL; Minvielle, S; Roché, H | 1 |
| Blackstein, M; Bowman, D; Burnell, M; Crump, M; Findlay, B; Levine, M; Norris, B; Palmer, MJ; Pritchard, KI; Shepherd, L; Skillings, J; Tonkin, K; Trudeau, M; Tu, D; Walde, D | 1 |
| Guan, JH; Huan, HY; Mao, F; Sun, Q; Zhou, YD | 1 |
| Chow, NH; Tsai, YS; Tzai, TS | 1 |
| Brock, CS; Eccles, S; Francis, N; Lim, A; McLean, SR; Nathan, M; Palmieri, C; Shousha, S | 1 |
| Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N | 1 |
| Baldan, A; Burra, P; Cardin, R; Cillo, U; Cristofori, C; Farinati, F; Giacomin, A; Girardi, L; Pivetta, G; Ragazzi, R; Sergio, A | 1 |
| Castiglione-Gertsch, M; Coates, AS; Colleoni, M; Collins, J; Crivellari, D; Forbes, JF; Gelber, RD; Goldhirsch, A; Holmberg, SB; Price, KN; Thürlimann, B | 1 |
| Cho, JY; Choi, SH; Lee, DK; Lee, KS; Lee, SI; Lee, SJ; Lim, JY; Paik, YH; Park, HJ; Yoon, DS | 1 |
| Antimi, M; Antonuzzo, L; Arcangeli, A; Banducci, S; Bellini, V; Biagioni, F; Bianchini, D; Bilancia, D; Bisagni, G; Biscottini, B; Boni, C; Bracci, R; Bravi, S; Bruno, L; Cabassi, A; Camera, S; Camisa, R; Canaletti, R; Carboni, M; Carlini, P; Carroccio, R; Cascinu, S; Catalano, G; Catalano, V; Cavalli, C; Cesari, M; Cognetti, F; Contu, A; Corgna, E; Cortesi, E; Croce, E; Dalla Mola, A; De Filippis, S; De Stefanis, M; Di Costanzo, F; Dinota, A; Enzo, MR; Farris, A; Figoli, F; Floriani, I; Foa, P; Fornarini, G; Francavilla, F; Frignano, M; Gasperoni, S; Gilli, G; Giunta, A; Grigniani, F; Ionta, MT; Italia, M; Labianca, R; Lastraioli, E; Leoni, M; Lungarotti, F; Luppi, G; Manzione, L; Masoni, L; Massidda, B; Mela, M; Messerini, L; Monzio Compagnoni, B; Muscogiuri, A; Natalini, G; Nelli, F; Nicolosi, A; Oldani, S; Olgiati, A; Olivetti, A; Orselli, G; Pandolfi, U; Papiani, G; Pazzola, A; Piga, A; Pisani Leretti, A; Porrozzi, S; Recchia, F; Romiti, A; Rondini, E; Rossetti, R; Rovei, R; Saggese, M; Sarobba, MG; Scipioni, L; Strafiuso, G; Tomao, S; Tonato, M; Torri, V; Trignano, M; Zironi, S | 1 |
| Hino, N; Ikushima, Y; Miyake, H; Ogasawara, T; Ohura, R; Sohnaka, Y; Tsuyuguchi, M; Wada, D; Yamamoto, Y; Yamasaki, S | 1 |
| Arima, N; Iwase, H; Kai, K; Miyayama, H; Nishimura, R; Yamamoto, Y | 1 |
| Igawa, M; Kadena, H; Ueda, M; Usui, T | 1 |
| Hsu, CY; Jan, JS; Lin, JC | 1 |
| Fujimoto, A; Ishihara, O; Itoyama, S; Kinoshita, K; Saitou, M; Takeda, S | 1 |
| Amoroso, D; Bertelli, G; Bruzzi, P; Campora, E; Del Mastro, L; Pronzato, P; Queirolo, P; Sertoli, MR; Venturini, M; Vigani, A | 1 |
| Botti, C; Cavaliere, R; Cognetti, F; Lopez, M; Scinto, AF; Vici, P | 1 |
| Gertenbach, U; Hohenfellner, R; Huber, C; Meyenburg, W; Stöckle, M; Thüroff, JW; Voges, G; Wellek, S | 1 |
| Devaux, Y; Fargeot, P; Fumoleau, P; Kerbrat, P; Mercier, M; Mihura, J; Namer, M; Schraub, S; Vo Van, ML | 1 |
| Bliss, J; Coombes, RC; Marty, M; Wils, J; Woods, E | 1 |
| Cabarrot, E; Gedouin, D; Gérard, JP; Goudier, MJ; Héry, M; Jacquin, JP; Monnier, A; Namer, M; Plat, F; Serin, D | 1 |
| Bajetta, E; Ballatore, P; Bochicchio, AM; Carnaghi, C; Di Bartolomeo, M; Gebbia, V; Mazzaferro, V; Somma, L; Tumolo, S; Visini, M | 1 |
| Asaishi, K; Hirata, K; Masuoka, H; Narimatsu, E; Okazaki, A; Okazaki, M; Okazaki, Y; Toda, K; Yamada, T | 1 |
| Biakhov, MIu; Buianov, SS; Dobrovol'skaia, NIu; Voznyĭ, EK | 1 |
| Gertenbach, U; Hohenfellner, R; Huber, C; Meyenburg, W; Rossmann, M; Stöckle, M; Thüroff, JW; Voges, GE; Wellek, S | 1 |
| Kobayashi, H; Obata, K | 1 |
| Bastert, G; Huober, J; Junkermann, H; Kaufmann, M; Leppien, G; Otto, HF; Schmid, H; Sinn, HP | 1 |
| Asaishi, K; Hirata, K; Masuoka, H; Narimatsu, E; Okazaki, A; Okazaki, M; Toda, K | 1 |
| Chevallier, B; Chollet, P; Hurteloup, P; Olivier, JP; Roche, H | 1 |
| Bonneterre, J; Mercier, M | 1 |
| Ogawa, Y; Ogoshi, S; Ohmori, Y; Okazaki, Y; Tanaka, Y; Toki, T | 1 |
| Barrantes, JC; García, I; Lobo-Sanahuja, F; Santamaría, S | 1 |
| Aapro, M; Amadori, D; Bliss, JM; Chilvers, CE; Coombes, G; Coombes, RC; Espié, M; Ferreira, EP; Gambrosier, P; Marty, M; McArdle, C; Morvan, F; Pérez-López, FR; Richards, M; Vassilopoulos, P; Villar-Grimalt, A; Wils, J; Woods, EM | 1 |
| Andreoli, F; Borrelli, D; Bruno, L; Cini, G; de Leonardis, V; Fabbroni, S; Intini, C; Neri, B; Pernice, LM; Romano, S; Valeri, A | 1 |
| Baars, JW; Beijnen, JH; Holtkamp, MJ; Peterse, JL; Rodenhuis, S; Rutgers, EJ; Schornagel, JH; van der Wall, E | 1 |
| Andreyev, HJ; Cunningham, D; Hill, AS; Norman, AR; Padhani, AR; Ross, PJ; Webb, A | 1 |
| Yamazaki, N | 1 |
| Bouaziz, M; Boudaya, M; Daoud, J; Drira, MM; Elloumi, M; Frikha, M; Ghorbel, A; Jlidi, R; Kechaou, MS; Souissi, T | 1 |
| Cortés-Funes, H; García-Conde, J; Hornedo, J; Lluch, A; López, J; Sola, C; Solano, C | 1 |
| Arai, K; Imai, R; Ito, K; Kojima, K; Muro, H; Nakagami, K; Nakajima, N; Nishimura, K; Onogawa, S; Suzuki, M; Tohyama, K; Umeda, Y | 1 |
| Adachi, I; Kanda, K; Murai, H; Ogita, M; Saeki, T; Sano, M; Sasaki, Y; Shimoyama, M; Tabei, T; Takashima, S; Watanabe, T | 1 |
| Sakata, Y; Tsushima, K | 1 |
| Fukunaga, M; Hasegawa, S; Hirao, T; Imamoto, H; Kan, K; Kondo, M; Maruyama, H; Ohzato, H; Takatsuka, Y; Tono, T; Yamazaki, K; Yongman, K | 1 |
| Abu-Zahra, H; Arnold, A; Bowman, D; Bramwell, VH; Burnell, M; Findlay, B; Levine, MN; MacKenzie, R; Myles, J; Norris, BD; Ottaway, J; Pritchard, KI; Robert, J; Shepherd, LE; Tu, D; Vandenberg, T; Warr, D; Williams, CK | 1 |
| Baars, JW; Bakx, R; Borger, JH; Dalesio, O; Koning, CC; Nooijen, WJ; Peterse, JL; Richel, DJ; Rodenhuis, S; Rutgers, E; Schornagel, JH; van der Wall, E | 1 |
| Basser, RL; Begley, CG; Cebon, J; Collins, JP; Juttner, CA; Maher, DW; Olver, I; Russell, I; Szer, J; To, LB | 1 |
| Atkins, CD | 1 |
| Alonso, S; Armand, JP; Chouaki, N; Cortès-Funes, H; Cvitkovic, E; Fandi, A; Hasbini, A; Lianes, P; Mahjoubi, R; Raymond, E; Taamma, A | 1 |
| Chen, Z; Li, G; Liu, F | 1 |
| Azama, T; Furukawa, J; Katsumoto, Y; Morimoto, T; Nakaguchi, K; Okajima, S; Shingai, T; Sue, F; Yoshioka, S | 1 |
| Bliss, JM; Coombes, G; Coombes, RC; Fontaine, C; Marty, M; Morvan, F; Olmos, T; Pérez-López, FR; Vassilopoulos, P; Wils, JA; Woods, E | 1 |
| Chauvergne, J; Fervers, B; Fondrinier, E; Guastalla, JP; Haie-Meder, C; Lhommé, C; Resbeut, M | 1 |
| Bastert, G; Haas, R; Hohaus, S; Martin, S; Schlenk, RF; Schneeweiss, A; Voso, MT; Wallwiener, D | 1 |
| Bonavina, L; Incarbone, R; Peracchia, A; Via, A | 1 |
| Celik, S; Evrensel, T; Orhan, B; Samli, B; Tasdelen, I | 1 |
| Carder, P; Gooi, J; Nishikawa, H; Wilson, J | 1 |
| Blohmer, J; Breitbach, P; Elling, D; Heinrich, J; Köhler, U; Kohls, A; Krocker, J; Kümmel, S; Lichtenegger, W; Quass, J | 1 |
| Dai, A; Feng, J; Zheng, X | 1 |
| Anker, G; Bengtsson, NO; Bergh, J; Blomqvist, C; Erikstein, B; Holte, H; Kellokumpu-Lehtinen, P; Lidbrink, E; Lindman, H; Ljungman, P; Malmström, P; Nilsson, J; Ottosson, S; Salminen, E; Söderlund, G; Wiklund, T; Wilking, N; Wist, E | 1 |
| Asselain, B; Beuzeboc, P; Diéras, V; Dorval, T; Extra, JM; Jouve, M; Laurence, V; Mouret, E; Palangié, T; Pierga, JY; Pouillart, P; Scholl, S; Vincent-Salomon, A | 1 |
| Miyauchi, M; Nakajima, N; Ogawa, K; Oheda, Y; Ohno, K; Suzuki, M; Takahashi, M; Tsukamoto, T; Yamamoto, K; Yamamoto, N | 1 |
| Amoroso, D; Ballestrero, A; Boccardo, F; Brema, F; Ferrando, F; Genta, F; Mesiti, M; Patrone, F; Rinaldini, M; Rubagotti, A; Sismondi, P; Stura, P | 1 |
| de Jong, S; de Leij, LF; de Vries, EG; Mulder, NH; Ruiters, MH; Schröder, CP; van der Graaf, WT; van der Zee, AG; Wisman, GB | 1 |
| Bédard, EL; Brecevic, E; Dar, R; Inculet, RI; Malthaner, RA; Vincent, M | 1 |
| Esumi, K; Furukawa, H; Hoshida, Y; Ikeda, M; Imamura, H; Ishida, H; Kato, H; Kawasaki, T; Masuda, N; Masutani, S; Satomi, T; Shimizu, J; Tatsuta, M | 1 |
| Chung, NN; Hong, RL; Hsu, MM; Ko, JY; Lou, PJ; Lui, LT; Sheen, TS; Ting, LL; Wang, CC | 1 |
| Dunst, J; Haensgen, G | 1 |
| Glück, S | 1 |
| Kaneko, M; Oguchi, S; Saida, T; Uhara, H | 1 |
| Illiger, HJ; Ost, E | 1 |
| Abu-Zahra, H; Arnold, A; Bramwell, V; Findlay, B; Levine, MN; Perrault, D; Pritchard, K; Skillings, J; Warr, D | 1 |
| Amoroso, D; Boccardo, F; Castagnetta, L; Farris, A; Genta, F; Nenci, I; Piffanelli, A; Rubagotti, A; Sismondi, P; Traina, A | 1 |
| Carpano, S; Conti, EM; Di Lauro, L; Lopez, M; Natali, M; Tonini, G; Vici, P | 1 |
| Bachy, B; Caillaud, JM; Flamant, F; Gruner, M; Hemet, J; Lefur, R; Lemerle, J; Tron, P; Vannier, JP | 1 |
| Bombino, T; Brambilla, C; Ferrari, L; Gangeri, L; Rosso, S; Tamburini, M | 1 |
| Chang, AY; Chen, KY; Jame, JM; Law, CK; Li, WY; Lin, CZ; Zen, HG | 1 |
| Boccardo, F; Bruzzi, P; Cappellini, M; Isola, G; Nenci, I; Piffanelli, A; Rubagotti, A; Santi, L; Scanni, A; Sismondi, P | 1 |
| Asaishi, K; Hayasaka, H; Mikami, T; Narimatsu, E; Okazaki, A; Okazaki, M; Okazaki, Y; Sato, H; Toda, K; Watanabe, Y | 1 |
| Kolarić, K; Potrebica, V; Stanovnik, M | 1 |
12 review(s) available for epirubicin and Lymph Node Metastasis
| Article | Year |
|---|---|
Leiomyosarcoma of the parotid gland in an HIV-positive patient: therapeutic approach, clinical course and review of the literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Antiretroviral Therapy, Highly Active; Biomarkers, Tumor; Bone Neoplasms; Combined Modality Therapy; Epirubicin; Fatal Outcome; Female; HIV Infections; Humans; Ifosfamide; Immunohistochemistry; Leiomyosarcoma; Lung Neoplasms; Lymphatic Metastasis; Parotid Neoplasms; Radiotherapy | 2009 |
[Diagnosis and treatment of gastric cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Signet Ring Cell; Cisplatin; Endoscopy, Digestive System; Epirubicin; Esophagectomy; Fluorouracil; Gastrectomy; Gastric Mucosa; Humans; Laparoscopy; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Neoplasm, Residual; Stomach Neoplasms; Tomography, X-Ray Computed | 2010 |
Clear cell sarcoma of the ileum: report of a case and review of the literature.
Topics: Aged; Antibiotics, Antineoplastic; Biomarkers, Tumor; Calmodulin-Binding Proteins; CD56 Antigen; Chromosomal Proteins, Non-Histone; Combined Modality Therapy; DNA-Binding Proteins; Epirubicin; Female; Humans; Ileal Neoplasms; Ileum; In Situ Hybridization, Fluorescence; Lymph Nodes; Lymphatic Metastasis; RNA-Binding Protein EWS; RNA-Binding Proteins; S100 Proteins; Sarcoma, Clear Cell; SMARCB1 Protein; Transcription Factors; Translocation, Genetic; Treatment Outcome | 2012 |
Drug-HPMA-HuIg conjugates effective against human solid cancer.
Topics: Adult; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Epirubicin; Female; Heart Neoplasms; Heart Transplantation; Hemangiosarcoma; Hempa; Humans; Immunoglobulin G; Immunotherapy; Lymphatic Metastasis; Middle Aged; Neoplasms | 2003 |
Secondary acute leukemia following mitoxantrone-based high-dose chemotherapy for primary breast cancer patients.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Daunorubicin; Doxorubicin; Epirubicin; Female; Humans; Incidence; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Leukemia, Promyelocytic, Acute; Leukemia, Radiation-Induced; Lymphatic Metastasis; Melphalan; Middle Aged; Mitoxantrone; Neoplasms, Second Primary; Paclitaxel; Peripheral Blood Stem Cell Transplantation; Radiotherapy, Adjuvant; Thiotepa; Transplantation Conditioning; Transplantation, Autologous | 2003 |
[Adjuvant chemotherapy based on evidence-based medicine for breast cancer patients].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Epirubicin; Evidence-Based Medicine; Female; Fluorouracil; Guidelines as Topic; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Meta-Analysis as Topic; Methotrexate; Receptor, ErbB-2; Taxoids; Trastuzumab | 2006 |
[Chemotherapy for advanced adenocarcinoma of the skin: experience with combination chemotherapy and a review of the literature].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Administration Schedule; Epirubicin; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Paget Disease, Extramammary; Skin Neoplasms; Sweat Gland Neoplasms; Vincristine | 1997 |
[Treatment of recurrent gastric cancer].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Doxorubicin; Drug Administration Schedule; Epirubicin; Etoposide; Fluorouracil; Humans; Immunologic Factors; Irinotecan; Liver Neoplasms; Lymphatic Metastasis; Methotrexate; Mitomycin; Neoplastic Cells, Circulating; Peritoneal Neoplasms; Stomach Neoplasms | 1998 |
[Standards, options and recommendations: concomitant radiochemotherapy for cancer of the cervix: a critical analysis of the literature and update of SOR].
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; Epirubicin; Female; Fluorouracil; Humans; Hydroxyurea; Lymphatic Metastasis; Multicenter Studies as Topic; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Practice Guidelines as Topic; Prognosis; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome; Uterine Cervical Neoplasms | 1999 |
Recall phenomenon following epirubicin.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Arm; Breast Neoplasms; Carcinoma; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Extravasation of Diagnostic and Therapeutic Materials; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged | 1999 |
Simultaneous radiochemotherapy in cervical cancer: recommendations for chemotherapy.
Topics: Adult; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Mitomycin; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Recurrence, Local; Postoperative Care; Radiation-Sensitizing Agents; Radiotherapy Dosage; Randomized Controlled Trials as Topic; Risk Factors; Time Factors; Uterine Cervical Neoplasms | 2001 |
The worldwide perspective in the adjuvant treatment of primary lymph node positive breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Methotrexate; Middle Aged; Prognosis; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome; World Health Organization | 2001 |
110 trial(s) available for epirubicin and Lymph Node Metastasis
| Article | Year |
|---|---|
Effect of Epirubicin Plus Paclitaxel vs Epirubicin and Cyclophosphamide Followed by Paclitaxel on Disease-Free Survival Among Patients With Operable ERBB2-Negative and Lymph Node-Positive Breast Cancer: A Randomized Clinical Trial.
Topics: Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Paclitaxel; Prospective Studies; Receptor, ErbB-2 | 2023 |
High-Dose Chemotherapy With Hematopoietic Stem Cell Transplant in Patients With High-Risk Breast Cancer and 4 or More Involved Axillary Lymph Nodes: 20-Year Follow-up of a Phase 3 Randomized Clinical Trial.
Topics: Adult; Axilla; Breast; Breast Neoplasms; Cardiovascular Abnormalities; Child; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Hematopoietic Stem Cell Transplantation; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged | 2020 |
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Risk Factors; Survival Rate | 2018 |
Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; China; Clinical Protocols; Cyclophosphamide; Epirubicin; Everolimus; Feasibility Studies; Female; Fluorouracil; Humans; Letrozole; Lymphatic Metastasis; Neoadjuvant Therapy; Nitriles; Pilot Projects; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Research Design; Treatment Outcome; Triazoles; Tumor Burden | 2017 |
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cisplatin; Epirubicin; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Humans; Irinotecan; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Prognosis; Prospective Studies; Stomach Neoplasms; Survival Rate | 2019 |
Predictive factors determining neoadjuvant chemotherapy outcomes in breast cancer - a single center experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; DNA Topoisomerases, Type II; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Paclitaxel; Prognosis; Prospective Studies; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Taxoids | 2013 |
Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Cyclophosphamide; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Early Detection of Cancer; Epirubicin; Female; Finland; Fluorouracil; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Molecular Sequence Data; Mutation; Neoplasm Staging; Phosphatidylinositol 3-Kinases; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Vinblastine; Vinorelbine | 2013 |
A phase III adjuvant randomised trial of 6 cycles of 5-fluorouracil-epirubicine-cyclophosphamide (FEC100) versus 4 FEC 100 followed by 4 Taxol (FEC-T) in node positive breast cancer patients (Trial B2000).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Treatment Outcome | 2014 |
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a random
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Puerto Rico; Receptor, ErbB-2; Stroke Volume; Time Factors; Trastuzumab; Treatment Outcome; United States | 2013 |
Effects of the addition of gemcitabine, and paclitaxel-first sequencing, in neoadjuvant sequential epirubicin, cyclophosphamide, and paclitaxel for women with high-risk early breast cancer (Neo-tAnGo): an open-label, 2×2 factorial randomised phase 3 trial
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Gemcitabine; Humans; Kaplan-Meier Estimate; Logistic Models; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Paclitaxel; Proportional Hazards Models; Risk Factors; Time Factors; Treatment Outcome; Tumor Burden; United Kingdom | 2014 |
Circulating tumor cells predict survival in early average-to-high risk breast cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Docetaxel; Epirubicin; Female; Fluorouracil; Gemcitabine; Humans; Immunomagnetic Separation; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prospective Studies; Taxoids | 2014 |
Epirubicin combined with oxaliplatin and 5-day continuous infusion of 5-fluorouracil as a first-line treatment for metastatic gastric cancer: treatment outcomes and analysis of prognostic factors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retroperitoneal Neoplasms; Retrospective Studies; Stomach Neoplasms; Survival Rate; Young Adult | 2015 |
Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Fluorouracil; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Paclitaxel; Treatment Outcome; Young Adult | 2015 |
Neutrophil-guided dosing of anthracycline-cyclophosphamide-containing chemotherapy in patients with breast cancer: a feasibility study.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Feasibility Studies; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Neutrophils; Prognosis; Prospective Studies | 2015 |
Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Odds Ratio; Taxoids; Treatment Outcome | 2015 |
Comparison of prognostic and predictive impact of genomic or central grade and immunohistochemical subtypes or IHC4 in HR+/HER2- early breast cancer: WSG-AGO EC-Doc Trial.
Topics: Adult; Aged; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Epirubicin; Estrogen Receptor alpha; Female; Fluorouracil; Genetic Testing; Genomics; Humans; Immunohistochemistry; Ki-67 Antigen; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Prognosis; Receptor, ErbB-2; Receptors, Progesterone; Taxoids | 2016 |
Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Survival Analysis; Taxoids | 2016 |
Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Class I Phosphatidylinositol 3-Kinases; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Receptor, ErbB-2; Stomach Neoplasms; Survival Rate; Tumor Suppressor Protein p53 | 2016 |
Higher rate of severe toxicities in obese patients receiving dose-dense (dd) chemotherapy according to unadjusted body surface area: results of the prospectively randomized GAIN study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Mass Index; Body Surface Area; Breast Neoplasms; Capecitabine; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Febrile Neutropenia; Female; Humans; Lymphatic Metastasis; Obesity; Taxoids | 2016 |
Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HOR
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Receptor, ErbB-2; Taxoids; Young Adult | 2016 |
[Safety of adjuvant dose-dense chemotherapy with paclitaxel and epirubicin for high-risk breast cancer].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Nausea; Neoplasm Recurrence, Local; Neoplastic Cells, Circulating; Neutropenia; Paclitaxel; Survival Rate; Vomiting; Young Adult | 2008 |
Randomized trial of cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil with node-positive breast cancer in Japan.
Topics: Adenocarcinoma; Adenocarcinoma, Scirrhous; Adult; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Japan; Lymphatic Metastasis; Methotrexate; Middle Aged; Receptors, Estrogen; Survival Rate; Treatment Outcome; Young Adult | 2010 |
FEC versus sequential docetaxel followed by epirubicin/cyclophosphamide as adjuvant chemotherapy in women with axillary node-positive early breast cancer: a randomized study of the Hellenic Oncology Research Group (HORG).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Time Factors; Treatment Outcome | 2010 |
Dose-intensified epirubicin versus standard-dose epirubicin/cyclophosphamide followed by CMF in breast cancer patients with 10 or more positive lymph nodes: results of a randomised trial (GABG-IV E-93) - the German Adjuvant Breast Cancer Group.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Epidemiologic Methods; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Menopause, Premature; Methotrexate; Middle Aged; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome | 2010 |
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Receptor, ErbB-2; Survival Rate; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2009 |
Cyclophosphamide, epirubicin, and Fluorouracil versus dose-dense epirubicin and cyclophosphamide followed by Paclitaxel versus Doxorubicin and cyclophosphamide followed by Paclitaxel in node-positive or high-risk node-negative breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel | 2010 |
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Survival Rate; Taxoids; Trastuzumab; Young Adult | 2009 |
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Treatment Outcome; Young Adult | 2010 |
Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Models, Biological; Proportional Hazards Models; Prospective Studies; Receptors, Estrogen; Treatment Outcome | 2011 |
Mitotic activity and bone marrow micrometastases have independent prognostic value in node positive breast cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cisplatin; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Methotrexate; Middle Aged; Mitotic Index; Neoplasm Micrometastasis; Prognosis; Tamoxifen; Treatment Outcome | 2011 |
Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel.
Topics: Adolescent; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Endpoint Determination; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Plasminogen Activator Inhibitor 1; Prognosis; Prospective Studies; Risk Assessment; Taxoids; Urokinase-Type Plasminogen Activator; Young Adult | 2011 |
Epirubicin and paclitaxel with G-CSF support in first line metastatic breast cancer: a randomized phase II study of dose-dense and dose-escalated chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Epirubicin; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Paclitaxel; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Deoxycytidine; Docetaxel; Epirubicin; Female; Gemcitabine; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2011 |
Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Neoplasms, Second Primary; Quality of Life; Selective Estrogen Receptor Modulators; Tamoxifen; Taxoids | 2011 |
A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study.
Topics: Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Italy; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Prospective Studies; Survival Analysis; Taxoids | 2012 |
Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Capecitabine; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Finland; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoplasm Grading; Neoplasm Staging; Prospective Studies; Survival Analysis; Taxoids; Treatment Outcome | 2012 |
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Greece; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Paclitaxel; Proportional Hazards Models; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2012 |
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Survival Rate; Taxoids; Young Adult | 2012 |
A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study).
Topics: Adult; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Docetaxel; Epirubicin; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2013 |
Methotrexate-paclitaxel-epirubicin-carboplatin as second-line chemotherapy in patients with metastatic transitional cell carcinoma of the bladder pretreated with cisplatin-gemcitabine: a phase II study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Prospective Studies; Salvage Therapy; Survival Rate; Urinary Bladder Neoplasms | 2013 |
A clinical study on regional lymphatic chemotherapy using an activated carbon nanoparticle-epirubicin in patients with breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Apoptosis; Breast Neoplasms; Carcinoma, Ductal, Breast; Charcoal; Epirubicin; Female; Humans; Injections, Intralymphatic; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Nanoparticles; Neoplasm Staging; Prognosis | 2012 |
Sequential docetaxel as adjuvant chemotherapy for node-positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemoradiotherapy; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Taxoids; Treatment Outcome; Young Adult | 2013 |
Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Logistic Models; Lymphatic Metastasis; Menopause; Methotrexate; Middle Aged; Multivariate Analysis; Prospective Studies; Vincristine | 2002 |
Randomized trial comparing six versus three cycles of epirubicin-based adjuvant chemotherapy in premenopausal, node-positive breast cancer patients: 10-year follow-up results of the French Adjuvant Study Group 01 trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Heart Diseases; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Premenopause; Risk Factors; Survival Rate | 2003 |
Recurrent gastric adenocarcinoma with unusual metastatic localization and excellent response to docetaxel and 5-FU continuous infusion.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Cisplatin; Docetaxel; Epirubicin; Fluorouracil; Humans; Infusions, Intravenous; Lymphatic Metastasis; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Paclitaxel; Spleen; Splenic Neoplasms; Stomach Neoplasms; Taxoids; Treatment Outcome | 2003 |
Adjuvant treatment of breast cancer patients with 1-3 positive lymph nodes: vinorelbine plus epirubicin; vinorelbine plus epirubicin sequential followed up by paclitaxel; epirubicin plus cyclophosphamide; epirubicin plus cyclophosphamide sequential follow
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Vinblastine; Vinorelbine | 2003 |
Long-term cardiac follow-up in relapse-free patients after six courses of fluorouracil, epirubicin, and cyclophosphamide, with either 50 or 100 mg of epirubicin, as adjuvant therapy for node-positive breast cancer: French adjuvant study group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Heart; Heart Failure; Humans; Lymphatic Metastasis; Middle Aged; Prospective Studies; Stroke Volume; Ventricular Dysfunction, Left | 2004 |
Single-agent epirubicin as primary chemotherapy in T2-T3, N0-N2, M0 breast carcinoma: 6-year follow-up.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Humans; Italy; Lymphatic Metastasis; Mastectomy, Modified Radical; Mastectomy, Segmental; Middle Aged; Treatment Outcome | 2004 |
Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Humans; Immunohistochemistry; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Maximum Tolerated Dose; Menopause; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Risk Assessment; Survival Rate; Tamoxifen; Treatment Outcome | 2004 |
A phase II study of epirubicin, cisplatin and uracil-tegafur for advanced gastric carcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Drug Combinations; Epirubicin; Female; Humans; Leukopenia; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Nausea; Stomach Neoplasms; Survival Rate; Tegafur; Uracil | 2005 |
Long-term efficacy and toxicity of the FEC100 regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cost-Benefit Analysis; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Costs; Epirubicin; Female; Fluorouracil; Heart Diseases; Humans; Leukemia, Myelomonocytic, Acute; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Time Factors; Treatment Outcome | 2004 |
A phase II study on the safety and efficacy of 5-fluorouracil, epirubicin, cyclophosphamide (FEC) followed by paclitaxel in the adjuvant treatment of breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Neoplasms, Ductal, Lobular, and Medullary; Paclitaxel; Safety; Survival Rate; Treatment Outcome | 2005 |
Predictors of central nervous system metastasis in patients with metastatic breast cancer. A competing risk analysis of 579 patients treated with epirubicin-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Breast Neoplasms; Cisplatin; Epirubicin; Female; Humans; Incidence; L-Lactate Dehydrogenase; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Prognosis; Prospective Studies; Receptors, Estrogen; Risk Factors; Vindesine | 2005 |
Early prediction of response to chemotherapy in metastatic breast cancer using sequential 18F-FDG PET.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Cyclophosphamide; Epirubicin; Female; Fluorodeoxyglucose F18; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Positron-Emission Tomography; Prognosis; Radiopharmaceuticals; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Treatment Outcome | 2005 |
[Effect of preoperative lymphatic chemotherapy on Bcl-2 and Bax expression in axillary metastasis of breast cancer].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Apoptosis; Axilla; bcl-2-Associated X Protein; Breast Neoplasms; Carcinoma, Ductal, Breast; Epirubicin; Female; Humans; Injections, Intralymphatic; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Preoperative Care; Proto-Oncogene Proteins c-bcl-2 | 2005 |
Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Docetaxel; Epirubicin; Female; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Receptor, ErbB-2; Taxoids; Trastuzumab | 2006 |
[The feasibility of FEC (75) as adjuvant chemotherapy for Japanese breast cancer patients].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dexamethasone; Diarrhea; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Fluorouracil; Granisetron; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neutropenia; Vomiting, Anticipatory | 2005 |
Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cystectomy; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2006 |
[Impact of preoperative lymphatic chemotherapy on relapse and metastasis of breast cancer and its mechanism].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Apoptosis; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Combined Modality Therapy; Epirubicin; Fas Ligand Protein; fas Receptor; Female; Humans; Injections, Intralymphatic; Lymph Nodes; Lymphatic Metastasis; Mastectomy, Modified Radical; Middle Aged; Neoplasm Recurrence, Local; Preoperative Care; Single-Blind Method | 2005 |
Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95.
Topics: Adult; Aged; Amenorrhea; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Odds Ratio; Recombinant Proteins; Risk Assessment; Risk Factors; Stem Cells; Survival Analysis; Treatment Outcome | 2006 |
Prognostic index score and clinical prediction model of local regional recurrence after mastectomy in breast cancer patients.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Axilla; Bayes Theorem; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy, Modified Radical; Methotrexate; Middle Aged; Models, Biological; Multivariate Analysis; Neoplasm Recurrence, Local; Prognosis; Proportional Hazards Models; Receptors, Estrogen | 2006 |
Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Mastectomy, Segmental; Methotrexate; Middle Aged; Paclitaxel; Prognosis | 2006 |
Paclitaxel and epirubicin followed by cyclophosphamide, methotrexate and 5-fluorouracil for patients with stage IIIC breast cancer with ten or more involved axillary lymph nodes.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Paclitaxel; Survival Analysis | 2006 |
Multicenter phase II trial of accelerated cisplatin and high-dose epirubicin followed by surgery or radiotherapy in patients with stage IIIa non-small-cell lung cancer with mediastinal lymph node involvement (N2-disease).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinum; Middle Aged; Pneumonectomy; Survival Analysis | 2006 |
Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 rando
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Feasibility Studies; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Survival Rate; Taxoids; Treatment Outcome | 2007 |
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Tamoxifen; Taxoids; Treatment Outcome | 2006 |
[Efficacy of activated charcoal-epirubicin suspension for treatment of breast cancer with axillary metastasis].
Topics: Adult; Aged; Antibiotics, Antineoplastic; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Charcoal; Epirubicin; Female; Humans; Injections, Intralymphatic; Lymph Nodes; Lymphatic Metastasis; Middle Aged | 2006 |
Effects of a treatment gap during adjuvant chemotherapy in node-positive breast cancer: results of International Breast Cancer Study Group (IBCSG) Trials 13-93 and 14-93.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Receptors, Estrogen; Tamoxifen | 2007 |
Adjuvant treatment of high-risk, radically resected gastric cancer patients with 5-fluorouracil, leucovorin, cisplatin, and epidoxorubicin in a randomized controlled trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Stomach Neoplasms; Survival Analysis | 2007 |
Phase II study of cisplatin, epirubicin, UFT, and leucovorin (PELUF) as first-line chemotherapy in metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Follow-Up Studies; Humans; Leucovorin; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Peritoneal Neoplasms; Stomach Neoplasms; Survival Analysis; Tegafur; Time Factors; Treatment Outcome; Uracil | 2007 |
Epirubicin-vinorelbine vs FEC100 for node-positive, early breast cancer: French Adjuvant Study Group 09 trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Cyclophosphamide; Disease Progression; Epirubicin; Female; Fluorouracil; France; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Survival Analysis; Vinblastine; Vinorelbine | 2007 |
Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Chemotherapy, Adjuvant; Docetaxel; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prospective Studies; Taxoids | 2007 |
A dose escalation trial of adjuvant cyclophosphamide and epirubicin in combination with 5-fluorouracil using G-CSF support for premenopausal women with breast cancer involving four or more positive nodes.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Premenopause | 2007 |
Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Topics: Adult; Aged; Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Estrogens; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Neoplasms, Second Primary; Paclitaxel; Peripheral Nervous System Diseases; Tamoxifen | 2008 |
Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Survival Analysis; Survivors; Tamoxifen | 2009 |
Salvage chemotherapy with docetaxel and epirubicin for advanced/metastatic gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Hematologic Diseases; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence, Local; Patient Selection; Platinum Compounds; Salvage Therapy; Severity of Illness Index; Stomach Neoplasms; Taxoids; Treatment Outcome | 2007 |
Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Cisplatin; Diarrhea; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Gastrectomy; Hematologic Diseases; Humans; Immunohistochemistry; Italy; Kaplan-Meier Estimate; Leucovorin; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Mucositis; Neoplasm Staging; Patient Compliance; Prognosis; Proportional Hazards Models; Stomach Neoplasms; Treatment Outcome; Vomiting | 2008 |
M-VEC (methotrexate, vinblastine, epirubicin, and cisplatin) with granulocyte colony-stimulating factor for the treatment of urothelial cancer: an effective and safe chemotherapy regimen.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Cisplatin; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Injections, Intravenous; Kidney Neoplasms; Kidney Pelvis; Lung Neoplasms; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Recombinant Proteins; Tomography, X-Ray Computed; Ureteral Neoplasms; Urinary Bladder Neoplasms; Vinblastine; World Health Organization | 1994 |
Neoadjuvant chemotherapy for advanced nasopharyngeal carcinoma.
Topics: Actuarial Analysis; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Epirubicin; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Nasopharyngeal Neoplasms; Remission Induction; Survival Analysis | 1995 |
Randomized cooperative study of perioperative chemotherapy in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Italy; Lymph Nodes; Lymphatic Metastasis; Methotrexate; Middle Aged; Multivariate Analysis; Postmenopause; Receptors, Estrogen; Survival Rate; Tamoxifen | 1995 |
[The role of M-VAC polychemotherapy in the treatment of advanced urothelial carcinoma of the bladder].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma in Situ; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Doxorubicin; Epirubicin; Female; Humans; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Palliative Care; Remission Induction; Urinary Bladder Neoplasms; Vinblastine | 1993 |
Premenopausal patients with node-positive resectable breast cancer. Preliminary results of a randomised trial comparing 3 adjuvant regimens: FEC 50 x 6 cycles vs FEC 50 x 3 cycles vs FEC 75 x 3 cycles. The French Adjuvant Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Premenopause; Stereoisomerism; Survival Rate | 1993 |
Design and rationale of a randomised comparison of cyclophosphamide, methotrexate and fluorouracil vs fluorouracil, epirubicin and cyclophosphamide in node-positive premenopausal women with operable breast cancer. A trial of the International Collaborativ
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intravenous; Lymphatic Metastasis; Methotrexate; Middle Aged; Premenopause | 1993 |
Postmenopausal patients with node-positive resectable breast cancer. Tamoxifen vs FEC 50 (6 cycles) vs FEC 50 (6 cycles) plus tamoxifen vs control--preliminary results of a 4-arm randomised trial. The French Adjuvant Study Group.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Postmenopause; Survival Rate; Tamoxifen; Treatment Outcome | 1993 |
A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Neuroendocrine Tumors; Remission Induction | 1995 |
[Intra-arterial infusion chemotherapy for advanced or recurrent breast cancers].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Humans; Infusions, Intra-Arterial; Lymphatic Metastasis; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Recurrence, Local; Remission Induction | 1995 |
Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited: long-term results of a controlled prospective study and further clinical experience.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cystectomy; Doxorubicin; Epirubicin; Female; Humans; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Prospective Studies; Survival Rate; Urinary Bladder Neoplasms; Vinblastine | 1995 |
Results of adjuvant chemotherapy for invasive urothelial cancer with lymph-node metastasis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Doxorubicin; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Kidney Neoplasms; Kidney Pelvis; Longitudinal Studies; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Invasiveness; Survival Rate; Ureteral Neoplasms; Urinary Bladder Neoplasms; Urologic Neoplasms; Vinblastine | 1994 |
Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histologic response rate.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Ethinyl Estradiol; Female; Fever; Fluorouracil; Hematologic Diseases; Humans; Infections; Length of Stay; Lymphatic Metastasis; Mastectomy, Modified Radical; Middle Aged; Neoplasm Staging; Pilot Projects; Remission Induction | 1993 |
Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: results of a randomized trial. The International Collab
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Hematologic Diseases; Humans; Lymphatic Metastasis; Mastectomy; Methotrexate; Middle Aged; Nausea; Premenopause; Regression Analysis; Survival Analysis; Vomiting | 1996 |
Adjuvant chemotherapy after gastric resection in node-positive cancer patients: a multicentre randomised study.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Drug Administration Schedule; Epirubicin; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Leucovorin; Lymphatic Metastasis; Neoplasm Staging; Proportional Hazards Models; Recurrence; Stomach Neoplasms; Survival Rate; Time Factors | 1996 |
Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients.
Topics: Adult; Age Factors; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Feasibility Studies; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoplasm Staging; Receptors, Estrogen; Receptors, Progesterone; Remission Induction | 1996 |
A phase II study of high-dose epirubicin (EPI) plus cyclophosphamide (CPA) with G-CSF for breast cancer patients with visceral metastases or hormone-independent tumors: a trial of the Japan Clinical Oncology Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukopenia; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neutropenia; Prospective Studies; Receptors, Estrogen; Recombinant Proteins; Survival Rate; Thrombocytopenia | 1997 |
Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Premenopause; Survival Rate | 1998 |
Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Estrogen Antagonists; Female; Fluorouracil; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Radiotherapy, Adjuvant; Survival Rate; Tamoxifen; Thiotepa | 1998 |
Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Hematopoietic Stem Cell Transplantation; Humans; Leukapheresis; Leukocyte Count; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Platelet Count; Recombinant Proteins | 1995 |
Phase II trial combining mitomycin with 5-fluorouracil, epirubicin, and cisplatin in recurrent and metastatic undifferentiated carcinoma of nasopharyngeal type.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cisplatin; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Hematologic Diseases; Humans; Lymphatic Metastasis; Male; Middle Aged; Mitomycins; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Radiotherapy, Adjuvant; Survival Rate | 1999 |
[Influence of preoperative on gastric cancer tissues and cells].
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Preoperative Care; Stomach Neoplasms | 1997 |
Epirubicin plus tamoxifen versus tamoxifen alone in node-positive postmenopausal patients with breast cancer: A randomized trial of the International Collaborative Cancer Group.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Epirubicin; Female; Humans; London; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Second Primary; Paris; Postmenopause; Proportional Hazards Models; Survival Rate; Tamoxifen | 1999 |
Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Disease-Free Survival; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Leukapheresis; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Treatment Outcome | 1999 |
[Dose intensified adjuvant chemotherapy in high risk breast carcinoma with 4-9 positive lymph nodes].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Methotrexate; Neoplasm Staging; Prospective Studies | 2000 |
Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.
Topics: Acute Disease; Adult; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Infusions, Intravenous; Leukemia, Myeloid; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Proportional Hazards Models; Sweden; Thiotepa | 2000 |
Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Heart Diseases; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasms, Second Primary; Survival Rate | 2001 |
[Usefulness of ambulatory adjuvant chemotherapy with low-dose epirubicin in patients with axially-node positive breast cancer: Chiba Epirubicin Cooperative Study Group].
Topics: Adult; Ambulatory Care; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Survival Rate; Tamoxifen | 2001 |
Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Leukocytes; Lymphatic Metastasis; Middle Aged; Platelet Count; Recombinant Proteins; Telomerase; Telomere; Thiotepa | 2001 |
Induction chemotherapy with mitomycin, epirubicin, cisplatin, fluorouracil, and leucovorin followed by radiotherapy in the treatment of locoregionally advanced nasopharyngeal carcinoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Leucovorin; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Survival Analysis; Taiwan; Treatment Outcome | 2001 |
A pilot study of intensive cyclophosphamide, epirubicin and fluorouracil in patients with axillary node positive or locally advanced breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neutropenia; Pilot Projects | 1992 |
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Menopause; Methotrexate; Middle Aged; Neoplasm Proteins; Receptors, Estrogen; Tamoxifen | 1992 |
Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, estrogen receptor-positive breast cancer patients: results of a multicentric Italian study. Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Italy; Lymph Nodes; Lymphatic Metastasis; Menopause; Methotrexate; Middle Aged; Multicenter Studies as Topic; Multivariate Analysis; Prospective Studies; Random Allocation; Receptors, Estrogen; Tamoxifen | 1990 |
Controlled phase III clinical study of 4-epi-doxorubicin + 5-fluorouracil versus 5-fluorouracil alone in metastatic gastric and rectosigmoid cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Doxorubicin; Epirubicin; Female; Fluorouracil; Heart Diseases; Humans; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Rectal Neoplasms; Sigmoid Neoplasms; Stomach Neoplasms | 1986 |
109 other study(ies) available for epirubicin and Lymph Node Metastasis
| Article | Year |
|---|---|
Computed tomography reconstruction for evaluating response in axillary lymph nodes of breast cancer after neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Multidetector Computed Tomography; Neoadjuvant Therapy; Neoplasm, Residual; Paclitaxel; Retrospective Studies; Sensitivity and Specificity; Treatment Outcome | 2021 |
Early prediction of response to neoadjuvant chemotherapy using contrast-enhanced ultrasound in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Contrast Media; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Logistic Models; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Ultrasonography | 2021 |
Comparison of Efficacy of Adjuvant MEC (Methotrexate, Epirubicin and Cisplatin) and GC (Gemcitabine and Cisplatin) in Advanced Upper Tract Urothelial Carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Risk Factors; Survival Rate; Urologic Neoplasms | 2017 |
Modified weekly regimen of cisplatin, epirubicin and paclitaxel induced a durable response in two cases of metastatic extramammary Paget's disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Drug Administration Schedule; Epirubicin; Genital Neoplasms, Male; Groin; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Male; Paclitaxel; Paget Disease, Extramammary; Scrotum; Skin Neoplasms; Treatment Outcome | 2017 |
Adjuvant endocrine therapy alone in patients with node-positive, luminal A type breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Epirubicin; Feasibility Studies; Female; Humans; Ki-67 Antigen; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Propensity Score; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Survival Analysis | 2017 |
Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cohort Studies; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Stomach Neoplasms | 2017 |
Predictive Value of Circulating Tumor Cells for Evaluating Short- and Long-Term Efficacy of Chemotherapy for Breast Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Middle Aged; Neoplastic Cells, Circulating; Predictive Value of Tests; Prognosis; ROC Curve | 2017 |
Epirubicin-loaded polymeric micelles effectively treat axillary lymph nodes metastasis of breast cancer through selective accumulation and pH-triggered drug release.
Topics: Animals; Antibiotics, Antineoplastic; Axilla; Cell Line, Tumor; Drug Delivery Systems; Drug Liberation; Epirubicin; Female; Hydrogen-Ion Concentration; Lymphatic Metastasis; Mammary Neoplasms, Experimental; Mice, Inbred BALB C; Mice, Nude; Micelles; Polymers | 2018 |
The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anastomotic Leak; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Databases, Factual; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Gastrectomy; Hospitals, University; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Predictive Value of Tests; Prognosis; Prospective Studies; Stomach Neoplasms; United Kingdom | 2014 |
Combination chemotherapy for metastatic extramammary Paget disease.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Anus Neoplasms; Bone Neoplasms; Carboplatin; Combined Modality Therapy; Epirubicin; Female; Fluorouracil; Genital Neoplasms, Male; Humans; Liver Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Paget Disease, Extramammary; Retrospective Studies; Treatment Outcome; Vincristine; Vulvar Neoplasms | 2014 |
Adjuvant high-dose chemotherapy with autologous hematopoietic stem cell support for high-risk primary breast cancer: results from the Italian national registry.
Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Gene Expression; Humans; Italy; Lymphatic Metastasis; Middle Aged; Mitoxantrone; Peripheral Blood Stem Cell Transplantation; Receptor, ErbB-2; Registries; Risk; Survival Analysis; Transplantation, Autologous | 2014 |
Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Endosonography; England; Epirubicin; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Hospital Mortality; Humans; Kaplan-Meier Estimate; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Positron-Emission Tomography; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Comparison of efficacy and toxicity of first line chemotherapy with or without epirubicin for patients with advanced stage soft tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Child; Cisplatin; Deoxycytidine; Doxorubicin; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Ifosfamide; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Grading; Neoplasm Recurrence, Local; Paclitaxel; Prognosis; Retrospective Studies; Sarcoma; Survival Rate; Young Adult | 2013 |
The Impact of Positive Margins on Outcome Among Patients With Gastric Cancer Treated With Radiation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Epirubicin; Female; Gastrectomy; Humans; Lymphatic Metastasis; Male; Margins of Excision; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Proportional Hazards Models; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Stomach Neoplasms; Survival Rate | 2016 |
A nomogram for predicting locoregional recurrence in primary breast cancer patients who received breast-conserving surgery after neoadjuvant chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Nomograms; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; ROC Curve; Survival Rate; Taxoids | 2014 |
Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.
Topics: Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Multicenter Studies as Topic; Outcome Assessment, Health Care; Paclitaxel; Prospective Studies; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Reproducibility of Results; Retrospective Studies | 2014 |
[Treatment and prognosis of 117 patients with advanced urothelial carcinoma of the bladder].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carboplatin; Carcinoma, Transitional Cell; Cisplatin; Cyclophosphamide; Deoxycytidine; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Gemcitabine; Humans; Leukopenia; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Retrospective Studies; Survival Rate; Thrombocytopenia; Urinary Bladder Neoplasms; Urothelium | 2014 |
The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; India; Induction Chemotherapy; Lymphatic Metastasis; Medical Records; Middle Aged; Molecular Targeted Therapy; Neoadjuvant Therapy; Neoplasm Staging; Postmenopause; Premenopause; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Rural Population; Tertiary Care Centers; Treatment Outcome | 2014 |
Relationship of body mass index with prognosis in breast cancer patients treated with adjuvant radiotherapy and chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axilla; Body Mass Index; Breast Neoplasms; Breast Neoplasms, Male; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Mastectomy, Modified Radical; Middle Aged; Neoplasm Metastasis; Obesity; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate; Thinness; Treatment Outcome | 2014 |
Multidisciplinary management of small cell carcinoma of the breast: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Breast Neoplasms; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Epirubicin; Etoposide; Female; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Mastectomy, Modified Radical; Middle Aged; Neoadjuvant Therapy; Radiotherapy, Adjuvant; Time Factors; Treatment Outcome; Ultrasonography, Mammary | 2014 |
Prognostic factors in operable breast cancer treated with neoadjuvant chemotherapy: towards a quantification of residual disease.
Topics: Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Confounding Factors, Epidemiologic; Cyclophosphamide; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Follow-Up Studies; France; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Neoplasm, Residual; Prognosis; Retrospective Studies; Risk Factors; Taxoids; Treatment Outcome | 2015 |
Decreased Overall and Bladder Cancer-Specific Mortality with Adjuvant Chemotherapy After Radical Cystectomy: Multivariable Competing Risk Analysis.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cystectomy; Deoxycytidine; Epirubicin; Follow-Up Studies; Gemcitabine; Humans; Lymphatic Metastasis; Methotrexate; Neoadjuvant Therapy; Risk Assessment; Survival Rate; Urinary Bladder Neoplasms; Vinblastine | 2016 |
Minkowski functionals: An MRI texture analysis tool for determination of the aggressiveness of breast cancer.
Topics: Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Biopsy; Breast Neoplasms; Cyclophosphamide; Docetaxel; Drug Therapy; Epirubicin; Female; Humans; Image Processing, Computer-Assisted; Lymphatic Metastasis; Magnetic Resonance Imaging; Middle Aged; Prognosis; Reproducibility of Results; Retrospective Studies; Software; Statistics, Nonparametric; Taxoids; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
Evaluation of the tracing effect of carbon nanoparticle and carbon nanoparticle-epirubicin suspension in axillary lymph node dissection for breast cancer treatment.
Topics: Adenocarcinoma, Mucinous; Antibiotics, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Medullary; Case-Control Studies; Charcoal; Combined Modality Therapy; Epirubicin; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Nanoparticles; Neoplasm Invasiveness; Neoplasm Staging; Prognosis | 2016 |
A Nomogram for Predicting the Pathological Response of Axillary Lymph Node Metastasis in Breast Cancer Patients.
Topics: Adult; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Gene Expression; Humans; Ki-67 Antigen; Logistic Models; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Nomograms; Paclitaxel; Prognosis; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; ROC Curve; Sentinel Lymph Node Biopsy; Trastuzumab; Tumor Burden | 2016 |
MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Epirubicin; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Immunoenzyme Techniques; Lymphatic Metastasis; Matrix Metalloproteinases, Membrane-Associated; Mice; Mice, Nude; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Retrospective Studies; Survival Rate; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
[Adjuvant epirubicin and cyclophosphamide followed by weekly paclitaxel for Japanese women with node-positive breast cancer: a multi-institutional feasibility study].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Feasibility Studies; Female; Humans; Japan; Lymphatic Metastasis; Middle Aged; Paclitaxel; Time Factors | 2008 |
Simultaneous multitarget irradiation using helical tomotherapy for advanced hepatocellular carcinoma with multiple extrahepatic metastases.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cisplatin; Combined Modality Therapy; Epirubicin; Feasibility Studies; Female; Humans; Iodized Oil; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Survival Rate | 2009 |
A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Fluorouracil; Gene Expression Profiling; Humans; Lymph Nodes; Lymphatic Metastasis; Multicenter Studies as Topic; Oligonucleotide Array Sequence Analysis; Postmenopause; Prognosis; Survival Rate; Treatment Outcome | 2009 |
p53 as a specific prognostic factor in triple-negative breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Prognosis; Proportional Hazards Models; Receptor, ErbB-2; Tumor Suppressor Protein p53 | 2009 |
Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.
Topics: Adult; Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Breast Neoplasms; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Ki-67 Antigen; Lymphatic Metastasis; Middle Aged; Prognosis; Receptors, Estrogen; Taxoids; Treatment Outcome | 2009 |
Feasibility of AC/EC followed by weekly paclitaxel in node-positive breast cancer in Japan.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Humans; Japan; Lymphatic Metastasis; Middle Aged; Paclitaxel | 2009 |
[Study on predictors of long term results for neo-adjuvant chemotherapy in locally advanced breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Prognosis; Retrospective Studies; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
[Efficacy of neoadjuvant chemotherapy with FEC and TEC regimen on breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Paclitaxel; Remission Induction; Survival Rate | 2009 |
[Neoadjuvant chemotherapy of FLEEOX regimen for unresectable gastric cancer resulting from advanced abdominal lymph nodes metastases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Leucovorin; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Stomach Neoplasms; Treatment Outcome | 2009 |
[Pediatric nasopharyngeal carcinoma: Anatomoclinic aspects, therapeutic results and evolutive particularities].
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma; Chemotherapy, Adjuvant; Child; Cisplatin; Cobalt Radioisotopes; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Nasopharyngeal Neoplasms; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasms, Radiation-Induced; Neoplasms, Second Primary; Radioisotope Teletherapy; Radiotherapy, Conformal; Retrospective Studies; Treatment Outcome; Xerostomia; Young Adult | 2010 |
Premenopausal hormone-responsive breast cancer with extensive axillary nodes involvement: total estrogen blockade and chemotherapy.
Topics: Adult; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Docetaxel; Epirubicin; Estriol; Estrogen Antagonists; Female; Humans; Ifosfamide; Leuprolide; Lymphatic Metastasis; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Premenopause; Receptors, Estrogen; Receptors, Progesterone; Taxoids; Triazoles; Tumor Necrosis Factor Ligand Superfamily Member 15 | 2011 |
Expressions of topoisomerase IIα and BCRP in metastatic cells are associated with overall survival in small cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Cyclophosphamide; DNA Topoisomerases, Type II; DNA-Binding Proteins; Epirubicin; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Mediastinal Neoplasms; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Prospective Studies; Real-Time Polymerase Chain Reaction; RNA, Messenger; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; Vault Ribonucleoprotein Particles; Vincristine | 2011 |
Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Topics: Adult; Aged; Analysis of Variance; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; DNA Topoisomerases, Type II; DNA-Binding Proteins; Epirubicin; Female; Fluorouracil; Gene Amplification; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Ki-67 Antigen; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Odds Ratio; Oligonucleotide Array Sequence Analysis; Paclitaxel; Poly-ADP-Ribose Binding Proteins; Predictive Value of Tests; Proto-Oncogene Proteins c-myc; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Treatment Outcome; Ultrasonography, Mammary | 2011 |
Risk of thromboembolic events after perioperative chemotherapy versus surgery alone for esophageal adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Cisplatin; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Esophagectomy; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Perioperative Care; Prognosis; Prospective Studies; Risk Factors; Thromboembolism | 2012 |
Nonsurgical management of esophageal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Cohort Studies; Deoxycytidine; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Follow-Up Studies; Humans; Induction Chemotherapy; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Ubc9 expression predicts chemoresistance in breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Epirubicin; Female; Fluorouracil; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lymphatic Metastasis; Mastectomy; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Proportional Hazards Models; Remission Induction; Tumor Burden; Ubiquitin-Conjugating Enzymes; Up-Regulation | 2011 |
[Primary systemic therapy in breast cancer patients (2007-2010)].
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Carcinoma, Intraductal, Noninfiltrating; Carcinoma, Lobular; Carcinoma, Medullary; Carcinoma, Papillary; Chemotherapy, Adjuvant; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mastectomy; Mastectomy, Segmental; Middle Aged; Neoadjuvant Therapy; Neoplasm Grading; Neoplasm Staging; Neoplasm, Residual; Radiography; Retrospective Studies; Taxoids; Treatment Outcome | 2011 |
An osteogenesis imperfecta case with breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Humans; Lymphatic Metastasis; Mastectomy; Osteogenesis Imperfecta; Premenopause | 2014 |
A prognostic model to predict outcome of patients failing to achieve pathological complete response after anthracycline-containing neoadjuvant chemotherapy for breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma, Ductal, Breast; Cathepsin D; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Ki-67 Antigen; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Prognosis; Vinblastine; Vinorelbine; Young Adult | 2012 |
Prognostic significance of intraoperative chemotherapy and extensive lymphadenectomy in patients with node-negative gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Gastrectomy; Humans; Intraoperative Period; Leucovorin; Lymph Node Excision; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Prognosis; Retrospective Studies; Stomach Neoplasms; Survival Rate | 2012 |
[Invasive ductal carcinoma and chronic lymphocytic leukemia: a unique case of collision tumor in breast].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Epirubicin; Female; Follow-Up Studies; Humans; Immunohistochemistry; Leukemia, Lymphocytic, Chronic, B-Cell; Lymph Node Excision; Lymphatic Metastasis; Middle Aged; Neoplasms, Multiple Primary; Paclitaxel | 2011 |
Feasibility and toxicity of docetaxel before or after fluorouracil, epirubicin and cyclophosphamide as adjuvant chemotherapy for early breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Taxoids; Treatment Outcome | 2013 |
A population-based study on the patterns of use of different chemotherapy regimens in Swiss patients with early breast cancer.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Bridged-Ring Compounds; Capecitabine; Carboplatin; Confidence Intervals; Cyclophosphamide; Deoxycytidine; Doxorubicin; Epirubicin; Female; Fluorouracil; Gemcitabine; Health Services Accessibility; Humans; Logistic Models; Lymphatic Metastasis; Medication Adherence; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Odds Ratio; Paclitaxel; Receptors, Estrogen; Switzerland; Taxoids; Vinblastine; Vinorelbine | 2012 |
Platinum and anthracycline therapy for advanced cutaneous squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cisplatin; Doxorubicin; Epirubicin; Female; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Skin Neoplasms | 2013 |
Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Cystectomy; Doxorubicin; Epirubicin; Evidence-Based Medicine; Humans; Lymphatic Metastasis; Methotrexate; Neoplasm Invasiveness; Randomized Controlled Trials as Topic; Survival Analysis; Urinary Bladder Neoplasms; Vinblastine | 2002 |
Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome.
Topics: Aneuploidy; Antibiotics, Antineoplastic; Biopsy, Needle; Breast Neoplasms; Doxorubicin; Epirubicin; Female; Humans; Ki-67 Antigen; Lymphatic Metastasis; Menopause; Middle Aged; Mitosis; Neoplasm Staging; Predictive Value of Tests; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; S Phase; Treatment Outcome; Tumor Suppressor Protein p53 | 2003 |
Radiation therapy for esthesioneuroblastoma: rationale for elective neck irradiation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blindness; Bone Neoplasms; Carboplatin; Chemotherapy, Adjuvant; Child; Child, Preschool; Cisplatin; Cytarabine; Epirubicin; Esthesioneuroblastoma, Olfactory; Etoposide; Female; Humans; Lung Neoplasms; Lymphatic Irradiation; Lymphatic Metastasis; Male; Middle Aged; Nasal Cavity; Necrosis; Neoplasm Recurrence, Local; Nose Neoplasms; Radiotherapy Dosage; Radiotherapy, Adjuvant; Salvage Therapy; Spinal Cord Neoplasms; Survival Analysis | 2003 |
Clinical benefit of chemosensitivity test for patients with regional lymph node-positive esophageal squamous cell carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Drug Administration Schedule; Drug Screening Assays, Antitumor; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Neoplasm Recurrence, Local; Survival Analysis | 2003 |
Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Disease-Free Survival; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Paclitaxel; Randomized Controlled Trials as Topic; Receptors, Estrogen; Survival Rate; Treatment Outcome | 2004 |
Hypoxia-inducible factor 1 alpha in high-risk breast cancer: an independent prognostic parameter?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Life Tables; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Paclitaxel; Prednisone; Prognosis; Receptors, Progesterone; Risk; Survival Analysis; Tamoxifen; Taxoids; Transcription Factors; Vincristine | 2004 |
A pilot study of neoadjuvant chemotherapy with mitomycin C, etoposide, cisplatin, and epirubicin for adenocarcinoma of the cervix.
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Adenosquamous; Chemotherapy, Adjuvant; Cisplatin; Dose-Response Relationship, Drug; Epirubicin; Etoposide; Female; Follow-Up Studies; Humans; Hysterectomy; Lymphatic Metastasis; Middle Aged; Mitomycin; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Pilot Projects; Radiotherapy, Adjuvant; Statistics as Topic; Treatment Outcome; Uterine Cervical Neoplasms; Women's Health | 2004 |
[A long-surviving patient with Stage IV breast cancer with no recurrence after combined therapy of medroxy progesterone acetate (MPA) and intra-arterial infusion chemotherapy].
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Floxuridine; Humans; Infusions, Intra-Arterial; Lymphatic Metastasis; Mastectomy, Segmental; Medroxyprogesterone Acetate; Neoplasm Staging; Survivors; Tamoxifen | 2004 |
[Taxol based chemotherapy in the treatment of advanced gastric cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymph Nodes; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Remission Induction; Stomach Neoplasms | 2004 |
Q-TWiST analysis of cyclophosphamide, epirubicin, fluorouracil versus cyclophosphamide, methotrexate, fluorouracil treatment for premenopausal women with node-positive breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Clinical Trials, Phase III as Topic; Cyclophosphamide; Disease-Free Survival; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Premenopause; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome | 2005 |
Prognostic indicators in locally advanced gastric cancer (LAGC) treated with preoperative chemotherapy and D2-gastrectomy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Drug Administration Schedule; Epirubicin; Etoposide; Fluorouracil; Gastrectomy; Humans; Laparoscopy; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Care; Prognosis; Proportional Hazards Models; Stomach Neoplasms; Survival Rate | 2005 |
Weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Female; Humans; Immunohistochemistry; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Maximum Tolerated Dose; Menopause; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Risk Assessment; Survival Rate; Tamoxifen; Treatment Outcome | 2005 |
Prognostic predictors in breast cancer patients with postoperative 5-fluorouracil-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Dihydrouracil Dehydrogenase (NADP); Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Thymidylate Synthase | 2005 |
Dose-dense adjuvant chemotherapy for node-positive breast cancer in women 60 years and older: feasibility and tolerability in a subset of patients in a randomized trial.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Epirubicin; Feasibility Studies; Female; Filgrastim; Fluorouracil; Granulocyte Colony-Stimulating Factor; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Paclitaxel; Randomized Controlled Trials as Topic; Recombinant Proteins; Retrospective Studies | 2006 |
Neoadjuvant interstitial high-dose-rate (HDR) brachytherapy combined with systemic chemotherapy in patients with breast cancer.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brachytherapy; Breast; Breast Neoplasms; Carcinoma, Ductal; Carcinoma, Lobular; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Dose Fractionation, Radiation; Doxorubicin; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Mastectomy, Segmental; Methotrexate; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Retrospective Studies; Risk Factors; Taxoids; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
[Pilot study of primary systemic chemotherapy with docetaxel (DOC), epirubicin (EPI) and capecitabine (Xeloda) in patients with advanced breast cancer].
Topics: Adult; Aged; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Docetaxel; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Leukopenia; Lymph Nodes; Lymphatic Metastasis; Mastectomy; Middle Aged; Neutropenia; Pilot Projects; Taxoids | 2006 |
[Clinical examination of safety and effectiveness of primary chemotherapy with CEF followed by docetaxel in preoperative breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Breast Neoplasms; Breast Neoplasms, Male; Combined Modality Therapy; Cyclophosphamide; Docetaxel; Drug Administration Schedule; Drug Evaluation; Epirubicin; Female; Fluorouracil; Humans; Leukopenia; Lymphatic Metastasis; Male; Mastectomy, Segmental; Middle Aged; Nausea; Taxoids; Vomiting, Anticipatory | 2006 |
Preoperative clinical, mammographic and sonographic assessment of neoadjuvant chemotherapy response in breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Epirubicin; Female; Humans; Lymphatic Metastasis; Mammography; Middle Aged; Neoplasm Staging; Paclitaxel; Physical Examination; Retrospective Studies | 2006 |
[Successful antiemetic treatment of TSUMURA Rikkunshi-to Extract Granules for ethical use in addition to other antiemetic agents in neoadjuvant chemotherapy for an advanced breast cancer patient].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Dexamethasone; Drug Administration Schedule; Drugs, Chinese Herbal; Epirubicin; Female; Fluorouracil; Granisetron; Humans; Lymph Nodes; Lymphatic Metastasis; Mastectomy, Segmental; Metoclopramide; Middle Aged | 2006 |
Multiple cutaneous metastases from male breast carcinoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Combined Modality Therapy; Cyclophosphamide; Disease Progression; Doxorubicin; Epirubicin; Fatal Outcome; Fluorouracil; Humans; Lung Neoplasms; Lymph Node Excision; Lymphatic Metastasis; Male; Mastectomy, Radical; Megestrol Acetate; Middle Aged; Paclitaxel; Palliative Care; Skin Neoplasms | 2006 |
Infiltrating ductal carcinoma and synchronous malignant phyllodes tumour. Diagnostic and therapeutic approaches.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Magnetic Resonance Imaging; Mastectomy, Modified Radical; Mastectomy, Simple; Middle Aged; Neoplasms, Multiple Primary; Phyllodes Tumor; Radiotherapy, Adjuvant; Remission Induction | 2006 |
[Breast cancer in young women in the south of Tunisia].
Topics: Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Breast; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Mammography; Mastectomy; Methotrexate; Middle Aged; Multivariate Analysis; Neoplasm Staging; Prognosis; Radiotherapy, Adjuvant; Retrospective Studies; Risk Factors; Sensitivity and Specificity; Survival Analysis; Time Factors; Treatment Outcome; Tunisia | 2006 |
Feasibility and accuracy of sentinel lymph node biopsy after preoperative chemotherapy in breast cancer patients with documented axillary metastases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy, Fine-Needle; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Doxorubicin; Epirubicin; False Negative Reactions; Feasibility Studies; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Preoperative Care; Sentinel Lymph Node Biopsy; Time Factors; Ultrasonography, Mammary | 2007 |
Prediction of metastatic relapse in node-positive breast cancer: establishment of a clinicogenomic model after FEC100 adjuvant regimen.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Genomics; Humans; Lymphatic Metastasis; Middle Aged; Prognosis; Retrospective Studies | 2008 |
[Dose dense chemotherapy in the postoperative adjuvant treatment for breast cancer].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Docetaxel; Dose-Response Relationship, Drug; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lymphatic Metastasis; Mastectomy; Middle Aged; Nausea; Neutropenia; Paclitaxel; Postoperative Period; Retrospective Studies; Taxoids | 2007 |
Does HER2 immunoreactivity provide prognostic information in locally advanced urothelial carcinoma patients receiving adjuvant M-VEC chemotherapy?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Humans; Immunohistochemistry; Lymphatic Metastasis; Male; Methotrexate; Middle Aged; Proportional Hazards Models; Receptor, ErbB-2; Time Factors; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium; Vinblastine | 2007 |
Metastatic ductal eccrine adenocarcinoma masquerading as an invasive ductal carcinoma of the male breast.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Cyclophosphamide; Diphosphonates; Eccrine Glands; Epirubicin; Fluorouracil; Humans; Ibandronic Acid; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Male; Radiotherapy; Sweat Gland Neoplasms; Tamoxifen; Tomography, X-Ray Computed | 2007 |
Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness.
Topics: Aged; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Enzyme-Linked Immunosorbent Assay; Epirubicin; Female; Fibroblast Growth Factor 2; Humans; Infusions, Intra-Arterial; Iodized Oil; Liver Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neovascularization, Pathologic; Prognosis; Proportional Hazards Models; Statistics, Nonparametric; Survival Rate; Urokinase-Type Plasminogen Activator; Vascular Endothelial Growth Factor A | 2008 |
[A case of occult breast cancer successfully treated by capecitabine in combination with weekly paclitaxel followed by FEC (75)].
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cyclophosphamide; Deoxycytidine; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Paclitaxel; Positron-Emission Tomography; Treatment Outcome | 2008 |
Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin-docetaxel neoadjuvant chemotherapy: a cohort study.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cohort Studies; Disease-Free Survival; Docetaxel; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Retrospective Studies; Taxoids | 2009 |
[A case of ovarian malignant Sertoli-Leidig cell tumor treated with CBDCA, etoposide and epirubicin chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Combined Modality Therapy; Epirubicin; Etoposide; Female; Humans; Lymphatic Metastasis; Middle Aged; Ovarian Neoplasms; Remission Induction; Sertoli-Leydig Cell Tumor | 1995 |
Prognostic value of lymph node metastases after neoadjuvant chemotherapy for large-sized operable carcinoma of the breast.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma; Chemotherapy, Adjuvant; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Female; Follow-Up Studies; Humans; Lymph Node Excision; Lymphatic Metastasis; Mastectomy, Segmental; Middle Aged; Multivariate Analysis; Neoplasm Recurrence, Local; Neoplasm Staging; Preoperative Care; Prognosis; Prospective Studies; Radiotherapy, Adjuvant; Remission Induction | 1995 |
[Comparison of the effectiveness and toxicity of parenteral and oral vepesid in the treatment of disseminated breast cancer].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Etoposide; Female; Humans; Injections, Intravenous; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Time Factors | 1995 |
[Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cell Division; Cell Survival; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Dose-Response Relationship, Drug; Epirubicin; Female; Humans; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Premedication | 1994 |
[The significance of intra-arterial infusion therapy for neoadjuvant chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Infusions, Intra-Arterial; Lymphatic Metastasis; Mitomycin; Prognosis | 1994 |
Response to chemotherapy after relapse in patients with or without previous adjuvant chemotherapy for breast cancer. The French Epirubicin Study Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Survival Rate; Treatment Outcome | 1993 |
A case of advanced male breast cancer successfully treated by 5-fluorouracil, epirubicin and cyclophosphamide chemotherapy combined with tamoxifen.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Fluorouracil; Humans; Lymphatic Metastasis; Male; Tamoxifen; Thoracic Neoplasms | 1995 |
Case report: pulmonary blastoma in children--response to chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cisplatin; Combined Modality Therapy; Epirubicin; Etoposide; Female; Humans; Ifosfamide; Lung Neoplasms; Lymphatic Metastasis; Pulmonary Blastoma; Vincristine | 1996 |
Squamous oesophageal cancer can be downstaged using protracted venous infusion of 5-fluorouracil with epirubicin and cisplatin (ECF).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Infusions, Intravenous; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Prospective Studies; Radiography; Remission Induction; Survival Analysis | 1995 |
[Evaluation of tumoral and lymph node response to neoadjuvant chemotherapy in undifferentiated nasopharyngeal carcinoma].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Chemotherapy, Adjuvant; Child; Cisplatin; Combined Modality Therapy; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Staging; Survival Analysis; Treatment Outcome | 1997 |
[High-dosage chemotherapy and autologous transplant of hematopoietic germ cells from peripheral blood in high-risk recurrence carcinoma of the breast (with >= or 10 involved axillary nodes at diagnosis) Preliminary results of the Solti 9301 cooperative st
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carboplatin; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Hematopoietic Stem Cell Transplantation; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Thiotepa; Transplantation, Autologous | 1997 |
[Liver metastases from breast cancer 14 years after radical mastectomy; successful treatment with hepatic arterial infusion chemotherapy and systemic endocrine therapy--a case report].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Epirubicin; Fadrozole; Female; Fluorouracil; Hepatic Artery; Humans; Infusion Pumps, Implantable; Infusions, Intra-Arterial; Liver Neoplasms; Lymphatic Metastasis; Mastectomy, Radical; Medroxyprogesterone; Mitomycin; Time Factors | 1997 |
[Intra-arterial chemotherapy to improve quality of life in cases of unresectable advanced or recurrent breast cancer].
Topics: Antibiotics, Antineoplastic; Breast Neoplasms; Drug Administration Schedule; Epirubicin; Female; Humans; Infusions, Intra-Arterial; Lymphatic Metastasis; Mammary Arteries; Neoplasm Recurrence, Local; Quality of Life; Subclavian Artery | 1998 |
Adjuvant chemotherapy with CEF versus CMF for node-positive breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Cytarabine; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Proportional Hazards Models; Randomized Controlled Trials as Topic; Research Design | 1998 |
[A case of multiple bone metastases from advanced breast cancer effectively treated with pamidronate].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Cyclophosphamide; Diphosphonates; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Middle Aged; Pamidronate; Skin Neoplasms | 1999 |
Current trends in the surgical treatment of esophageal and cardia adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; Cardia; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Diagnostic Imaging; Epirubicin; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Fluorouracil; Gastroesophageal Reflux; Humans; Italy; Leucovorin; Life Tables; Lymph Node Excision; Lymphatic Metastasis; Mediastinum; Neoadjuvant Therapy; Neoplasm Staging; Palliative Care; Postoperative Complications; Retrospective Studies; Stomach Neoplasms; Survival Analysis | 1999 |
Primary neuroendocrine small cell carcinoma of the breast.
Topics: Antineoplastic Combined Chemotherapy Protocols; Axilla; Biopsy, Needle; Breast Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Recurrence, Local; Radiotherapy | 2000 |
[A clinical report of high-dose epirubicin combined with cyclophosphamide and fluorouracil for advanced breast cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Medullary; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Neoplasm Staging | 1998 |
Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Axilla; Breast Neoplasms; Carcinoma, Ductal, Breast; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Multivariate Analysis; Neoadjuvant Therapy; Neoplasm Staging; Randomized Controlled Trials as Topic; Retrospective Studies; Survival Rate; Thiotepa; Treatment Outcome | 2000 |
Adjuvant chemotherapy with high-dose cyclophosphamide, etoposide and cisplatin intensification without progenitor cell support in breast cancer patients with ten or more involved nodes: 5-year results of a pilot trial.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Epirubicin; Female; Humans; Lymphatic Metastasis; Middle Aged; Pilot Projects | 2001 |
The role of surgery and postoperative chemoradiation therapy in patients with lymph node positive esophageal carcinoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Esophageal Neoplasms; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Radiotherapy, Adjuvant; Retrospective Studies; Survival Rate | 2001 |
[The significance of neoadjuvant intra-arterial chemotherapy for locally advanced breast cancer by different methods].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Humans; Infusions, Intra-Arterial; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Prognosis; Survival Rate | 2001 |
Docetaxel induced durable response in advanced extramammary Paget's disease: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Docetaxel; Drug Administration Schedule; Epirubicin; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Mitomycin; Paclitaxel; Paget Disease, Extramammary; Radiography; Scrotum; Skin Neoplasms; Taxoids; Vincristine | 2002 |
[Comparison of epirubicin and cyclophosphamide in 2-dose levels and classical CMF protocol in node-positive breast cancer. An adjuvant Phase III trial].
Topics: Administration, Oral; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Clinical Trials, Phase III as Topic; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Lymphatic Metastasis; Meta-Analysis as Topic; Methotrexate; Randomized Controlled Trials as Topic; Tamoxifen; Time Factors | 2002 |
5-Fluorouracil, epirubicin, and BCNU (FEB) in advanced measurable gastric cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Male; Middle Aged; Palliative Care; Stomach Neoplasms; Survival Analysis | 1990 |
Pancreatoblastoma: response to chemotherapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Child, Preschool; Cisplatin; Cyclophosphamide; Dactinomycin; Doxorubicin; Epirubicin; Etoposide; Female; Humans; Ifosfamide; Lymphatic Metastasis; Male; Pancreatic Neoplasms; Vinblastine; Vincristine | 1991 |
Two simple indexes used to evaluate the impact of therapy on the quality of life of patients receiving primary chemotherapy for operable breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Discriminant Analysis; Doxorubicin; Epirubicin; Female; Fluorouracil; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Mitoxantrone; Quality of Life; Reproducibility of Results; Surveys and Questionnaires | 1991 |
Nasopharyngeal carcinoma with bone marrow metastasis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma; Cisplatin; Combined Modality Therapy; Epirubicin; Female; Humans; Lymphatic Metastasis; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Recurrence, Local; Radiotherapy Dosage; Survival Rate | 1991 |
[Intra-arterial infusion chemotherapy of advanced breast cancer--effects and side effects of adriamycin, 4'-epi-adriamycin and THP-adriamycin].
Topics: Alopecia; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Epirubicin; Female; Humans; Infusions, Intra-Arterial; Leukopenia; Lymphatic Metastasis; Remission Induction; Thrombocytopenia | 1989 |